WHO Meeting of the Scientific and Technical Advisory Committee on Ebola Experimental Interventions – Briefing note
13 November 2014, Geneva, Switzerland
[Full text]
Following the emergence of Ebola virus disease (EVD) as a severe public health emergency for which no effective therapeutic or prophylactic interventions are available, the scientific community has proposed numerous experimental interventions, including: vaccines; convalescent blood and plasma; and medicines. None of these interventions have been evaluated for efficacy against EVD and therefore clinical studies to assess their safety and efficacy are required.

To facilitate and accelerate the appropriate clinical testing and generation of quality data of potential therapeutic interventions for EVD, WHO convened a meeting of the Scientific and Technical Advisory Committee for Ebola Experimental Interventions (STAC-EE) in Geneva, on 11-12 November 2014. The meeting was attended by experts in Ebola virus, preclinical and clinical testing, pharmacologists, sociologists, public health experts and regulators, as well as representatives from countries in West Africa.

STAC-EE reviewed the data on disease progression and the effect of some experimental products on 18 patients who were evacuated from West Africa to well-resourced facilities in other countries. Resulting data did not permit evaluation of efficacy of these interventions, and the comparatively high survival rate observed in these patients may be due to a variety of factors including the high standard of care they received.

Noting that the standard of care in Ebola affected countries varies between different treatment centres and even in the same centres over time while standard of care is being established, it was agreed that clinical trials should only be conducted in facilities able to provide consistently good standard of care. The number of such sites in West Africa, capable of providing such care and with suitable infrastructure to conduct clinical trials, is limited. Indeed, there have been far more proposals of products to be tested than availability of sites in which they could be tested. It was therefore imperative that STAC-EE prioritize the products for testing, mindful of time pressure and to avoid wastage of resources.

Collecting clinical data under the biosafety conditions required when treating Ebola necessitates careful consideration of the minimum data that should be collected, and since trials may be across multiple sites ideally such data collection forms should be harmonised. One minimal clinical data collection form was presented which will be used by several of the groups planning clinical trials. Other groups indicated a preference to develop a shorter and simpler form, but which would use several of the same data fields. These forms should be able to permit data pooling at a future date.

In addition, the STAC-EE highlighted the need for rapid Point-of-Care diagnostics to reduce the time gap between sample taking and results being received from laboratories.

Blood products
The Committee was informed of clinical trials of convalescent whole blood (CWB) and convalescent plasma (CP) that are ready to start in two affected countries, and are in planning stages in one, as well as of efforts by the international community to accelerate access to these therapies through capacity building for the national blood transfusion services.
The study in Guinea, organized by a consortium from Belgium, France, Guinea, and the United Kingdom, will evaluate CWB first and switch to CP once supplies become available. An additional study will evaluate CP only. Studies being planned in Sierra Leone will evaluate CP, but also make provision for use of CWB under compassionate use.
The STAC-EE noted that blood from survivors is likely to have variable qualitative and quantitative properties and that assay of anti-Ebola antibody titres for each donation is essential for interpretation of the trial, even if done retrospectively. Standardization of Ebola antibody assays is crucial to enable between-laboratory comparisons of data and reference materials are needed. Standard reporting of outcomes from the clinical trials is also essential and investigators confirmed that data would be collected using standard case report forms. This would facilitate subsequent meta-analysis.
The STAC-EE encouraged further investigation of the option of producing immunoglobulin (IG) from survivors, as IG may have benefits over CWB or CP as a public health intervention. As blood fractionation facilities do not exist in the affected countries, it will be necessary to consider use of facilities in other countries to pursue this option. Finally, it was agreed that reconstruction and then strengthening of blood systems in the affected countries is an important mid-term goal, with multiple benefits, and will provide a long-lasting legacy of the Ebola epidemic.

Medicines
WHO and partners receive daily proposals for potential products against EVD from the scientific community. Many of these have already been tested and shown to have no activity against the virus. It was agreed that these products, excluded for clinical trials at this stage, will be published on the WHO web site to enable scientists and developers to assess themselves whether further investigation is warranted.

One such product, the antiretroviral lamivudine, has been used in some of the affected countries stemming from a belief that it might have therapeutic effects in patients with EVD. However, data presented to the STAC-EE demonstrated that lamivudine has no antiviral activity against EVD and should therefore not be administered for the treatment of Ebola.
Since many products at various stages of development and with varying degrees of supportive data are being proposed to the affected countries and to WHO for consideration for use in the clinic, the STAC-EE developed a set of criteria regarding minimal preclinical and clinical data that should be met in order for a product to be considered for inclusion in clinical trials. This will be published on the WHO website.

While there are several products for which there is strong preclinical evidence (in monkeys) of efficacy against Ebola virus, most of these products are in early stages of development and the process for manufacturing scale-up has not yet been developed, hence, their availability is limited and intermittent. This group includes products such as monoclonal antibodies and small inhibitory RNA. There are other products which present less of a supply challenge because they are easier to make, or are already approved for other purposes, but currently for these the preclinical supportive data generally has shown limited activity either in, in vitro and/or in animal models. This group includes favipiravir, brincidofivir, toremifine and interferons. The committee recognised that the supporting data was weaker, some thought that the comparative ready availability of these products should be taken into account in prioritising such drugs for clinical evaluation, others thought that weak supporting data should lead one to study other drugs and that availability was not a reason to study drugs with weak supporting data.

The STAC-EE reviewed clinical protocols that were presented for trials of these four drugs by different groups, and provided scientific assessment. In addition a common clinical trial protocol for a randomized concurrently controlled study was reviewed. It was noted that there are essentially two proposed trial designs – (1) a historically controlled trial (non-randomized), that depending on the results could, under certain circumstances, lead to a subsequent randomized trial, and (2) the other being a randomized concurrently controlled trial that would start with a best available supportive care control arm, be evaluated using Bayesian analytic techniques, and would be adapted to incorporate an effective anti-Ebola treatment as soon as shown effective into the standard of care arm that all patients would receive. The feasibility of conduct and data quality derived from the two methodologies were vigorously debated, and it was generally conceded that each method had pros and cons for given situations, but that it was likely that for anti-Ebola treatments that did not have large effects, randomized concurrently controlled trials may be needed.

Of the drugs proposed, it was agreed that there were safety concerns for toremifene which need to be taken into account. It was also suggested that emerging data on brincidofivir should be reviewed by the committee as this may affect the prioritization of this drug, however the data is not yet available.

Next steps
The Committee noted that new data on these and other products are continuously emerging, making it necessary to review updated data in the near future.

STAC-EE Core Members *
Mike Kurilla, United States of America – Chair; Annick Antierens, Switzerland; Fred Binka, Ghana; Jeremy Farrar, United Kingdom; David Hueto, Benin; Aikichi Iwamoto, Japan; Gary Kobinger, Canada; Mandy Kader Konde, Guinea; Arnaud Fontanet , France; Line Matthiessen, European Commission; Jean-Marc Olive, France; Moussa Seydi, Senegal; Amadou Sall, Senegal
Christina Spiropoulou, United States of America; Cathy Zoon, United States of America
* Due to the short notice of the meeting on 11-12 November, some members were unable to attend and sent representatives as observers.
Meeting documentation
:: Agenda of the meeting
pdf, 441kb
:: List of participants
pdf, 230kb

UNICEF [to 15 November 2014]
http://www.unicef.org/media/media_71724.html

:: Mali: Emergency Directors emphasize critical contribution of humanitarian assistance and call for urgent funds to maintain the UN humanitarian air service
NEW YORK, 14 November 2014 – Addressing the media today following a three-day visit to Mali last week, the Emergency Directors of three humanitarian agencies, John Ging of OCHA, Afshan Khan of UNICEF, and Mabingue Ngom of UNFPA, said that Mali is at a crucial crossroads and that failure to act now to meet humanitarian needs may jeopardise the prospects for peace and stability in the country.

UNICEF: Ten Ebola Community Care Centers to open in Bombali district, Sierra Leone
GENEVA/FREETOWN, Sierra Leone, 14 November 2014 – Ten new Ebola Community Care Centers are due to open this week in Sierra Leone’s Bombali district as part of a new drive to bring Ebola care closer to communities.

Spike in measles deaths among children troubling, UNICEF says
NEW YORK/GENEVA, 13 November 2014 – UNICEF today expressed alarm at new data showing that the number of child deaths from measles jumped from an estimated 122,000 in 2012 to 145,700 in 2013.

Battle against Ebola being waged at community level: UNICEF
NEW YORK/DAKAR, 13 November 2014 – UNICEF said today the battle against Ebola must be waged, and will be won, at the heart of the community.

CDC/MMWR Watch [to 15 November 2014]
http://www.cdc.gov/media/index.html
:: CDC Releases New Reports on Ebola Cases in Liberia and the United States – Press Release – Friday, November 14, 2014

MMWR November 14, 2014 / Vol. 63 / No. 45::
Early Release
– Evidence for a Decrease in Transmission of Ebola Virus — Lofa County, Liberia, June 8–November 1, 2014
– Evidence for Declining Numbers of Ebola Cases — Montserrado County, Liberia, June–October 2014
– Ebola Virus Disease Cases Among Health Care Workers Not Working in Ebola Treatment Units — Liberia, June–August, 2014
– Ebola Epidemic — Liberia, March–October 2014
– Ebola Virus Disease Cluster in the United States — Dallas County, Texas, 2014
– Response to Importation of a Case of Ebola Virus Disease — Ohio, October 2014
– Possible Eradication of Wild Poliovirus Type 3 — Worldwide, 2012
– Progress Toward Regional Measles Elimination — Worldwide, 2000–2013

WHO: Statement on Tetanus Toxoid vaccine
13 November 2014
[Ful text]
WHO is concerned that misinformation circulating in the media about the Tetanus Toxoid vaccine could have a seriously negative impact on the health of women and children.
The Organization confirms that the Tetanus Toxoid (TT) vaccine is safe. The vaccine has been used in 52 countries, to immunize 130 million women to protect them and their newborn babies from tetanus. There is no HCG hormone in tetanus toxoid vaccines.
All vaccines administered by WHO and its partners have been prequalified. WHO’s prequalification programme is based on a strict, transparent, and scientifically sound assessment. The prequalification process includes a dossier review, consistency testing or performance evaluation and site visits to manufacturers. The process guarantees that the vaccine meets global standards of quality, safety, and efficacy.
The WHO Global Advisory Committee for Vaccine Safety recently published a report on immunization safety in pregnancy. The report stated that the vaccine has been widely and safely used for 40 years. Over that period, there has been a substantial decrease in neonatal tetanus and an increase in neonatal survival, and no signal of possible harm to pregnant women or their foetuses.
Tetanus is acquired when the spores of the bacterium Clostridium Tetani infect a wound or the umbilical stump of a newborn baby.
People of all ages can get tetanus but the disease is particularly common and serious in newborn babies (“neonatal tetanus”). Neonatal tetanus can be prevented by immunizing women of childbearing age with tetanus toxoid, either during pregnancy or outside of pregnancy. This protects the mother and – through a transfer of tetanus antibodies to the fetus – also her baby.
People who recover from tetanus do not have natural immunity and can be infected again and therefore need to be re-immunized. To be protected throughout life, an individual should receive 3 doses of diphtheria-tetanus-pertussis (DTP) in infancy, followed by a TT-containing booster at school-entry age (4-7 years), in adolescence (12-15 years), and in early adulthood.

WHO: Oslo meeting to garner increased global commitment to fight antimicrobial resistance
12-14 November 2014
[Excerpt]
Forty WHO Member States are meeting in Oslo on 13–14 November to give greater impulse to the fight against antimicrobial resistance. Their commitments and plans will feed into the WHO global action plan on antimicrobial resistance, up for agreement in 2015, and raise awareness of the need for global cooperation to tackle this silent but pervasive epidemic.
Resistance to a number of antimicrobials is a serious public health problem and it is affecting all countries. The Mekong countries, comprising Cambodia, Laos, Myanmar, Thailand and Vietnam, have for a number of years struggled with resistance to the best malaria medicine available, slowly reversing the important progress made in recent years in the fight against the disease. For drug-resistant TB, affecting about 700 000 people globally, there are few options and second line medicines are prohibitively priced for low- and middle-income countries. In high-income countries, resistance to common bacteria has turned mild ailments, such as urinary tract infection, into serious conditions treatable only with much costlier medicines…

GAVI Watch [to 15 November 2014]
http://www.gavialliance.org/library/news/press-releases/

:: Record numbers of children protected against leading causes of pneumonia with Gavi support
12 November 2014
“la Caixa” Foundation announces further €1m commitment to support pneumococcal vaccine

Industry Watch [to 15 November 2014]
Selected media releases and other selected content from industry.
:: Sanofi launches paediatric vaccine Shan5 in India
Business Standard | 10 November 2014
With the launch of Shan 5 in India 27 million babies born annually will have access to vaccination
Hyderabad, November 10, 2014
Sanofi Pasteur, the vaccines division of Sanofi, announced on Monday the launch of Shan5, its paediatric pentavalent vaccine developed and manufactured by its affiliate Shatha Biotechnic in India.
The vaccine received prequalification status from World Health Organisation (WHO) in April 2014.
“A significant number of babies born every year in India do not have access to modern vaccination programmes. The launch of Shan 5 in India means that 27 million babies born annually in India will have access to vaccination to protect from five potentially deadly diseases. By launching the vaccine Shantha will be contributing to filling this immunisation gap for the benefit of babies and their parents,” Harish Iyer, CEO of Hyderabad-based Shantha said…
:: Hilleman Laboratories signs MoU to fast track development of high-impact Oral Cholera Vaccine
10/11/2014
Hilleman Laboratories, an equal joint-venture partnership between Merck & Co. and Wellcome Trust, has signed a Memorandum of Understanding (MoU) with Bangladesh-based icddr,b (formerly the International Centre for Diarrheal Disease Research, Bangladesh), an international public health research organization, and Incepta Vaccine Ltd., leading pharmaceutical company in Bangladesh in a bid to fast track the clinical trials and product licensing and commercialization of the product….
… Dr. John Clemens, Executive Director, icddr,b said, “Cholera is a major public health problem in several developing countries and we are excited to have the opportunity to translate research into prevention. An important challenge is to understand the effectiveness of vaccines in resource poor, high-risk settings. For a variety of reasons, responses to oral vaccines in the developing world are often lower than those seen in industrialized countries. Optimizing a vaccine candidate to fit such settings and saving lives is synonymous with our philosophy.”…

IOM: Enabling Rapid and Sustainable Public Health Research During Disasters – Workshop Summary
The Forum on Medical and Public Health Preparedness for Catastrophic Events, in collaboration with the National Institutes of Health, the Office of the Assistant Secretary for Preparedness and Response, and the Centers for Disease Control and Prevention, hosted a public workshop that examined strategies and diversified partnerships to enable methodologically and ethically sound public health and medical research during future emergencies. Discussions supporting this new infrastructure included considerations of rapid funding mechanisms, data collection methods, rapid institutional review board approval processes, and integration of research into an operational response.

BMC Health Services Research
(Accessed 15 November 2014)
http://www.biomedcentral.com/bmchealthservres/content

Research article
Notifiable disease reporting among public sector physicians in Nigeria: a cross-sectional survey to evaluate possible barriers and identify best sources of information
Kathryn E Lafond1*, Ibrahim Dalhatu2, Vivek Shinde1, Ekanem E Ekanem3, Saidu Ahmed3, Patrick Peebles1, Mwenda Kudumu4, Milele Bynum4, Kabiru Salami4, Joseph Okeibunor4, Pamela Schwingl4, Anthony Mounts15, Abdulsalami Nasidi6 and Diane Gross1
Author Affiliations
BMC Health Services Research 2014, 14:568 doi:10.1186/s12913-014-0568-3
Published: 13 November 2014
Abstract (provisional)
Background
Since 2001, Nigeria has collected information on epidemic-prone and other diseases of public health importance through the Integrated Disease Surveillance and Response system (IDSR). Currently 23 diseases are designated as ?notifiable? through IDSR, including human infection with avian influenza (AI). Following an outbreak of highly pathogenic avian influenza A(H5N1) in Nigerian poultry populations in 2006 and one laboratory confirmed human infection in 2007, a study was carried out to describe knowledge, perceptions, and practices related to infectious disease reporting through the IDSR system, physicians? preferred sources of heath information, and knowledge of AI infection in humans among public sector physicians in Nigeria.
Methods
During November to December 2008, 245 physicians in six Nigerian cities were surveyed through in-person interviews. Survey components included reporting practices for avian influenza and other notifiable diseases, perceived obstacles to disease reporting, methods for obtaining health-related information, and knowledge of avian influenza among participating physicians.
Results
All 245 respondents reported that they had heard of AI and that humans could become infected with AI. Two-thirds (163/245) had reported a notifiable disease. The most common perceived obstacles to reporting were lack of infrastructure/logistics or reporting system (76/245, 31%), lack of knowledge among doctors about how to report or to whom to report (64/245, 26%), and that doctors should report certain infectious diseases (60/245, 24%). Almost all participating physicians (>99%) reported having a cell phone that they currently use, and 86% reported using the internet at least weekly.
Conclusions
Although the majority of physicians surveyed were knowledgeable of and had reported notifiable diseases, they identified many perceived obstacles to reporting. In order to effectively identify human AI cases and other infectious diseases through IDSR, reporting system requirements need to be clearly communicated to participating physicians, and perceived obstacles, such as lack of infrastructure, need to be addressed. Future improvements to the reporting system should account for increased utilization of the internet, as well as cell phone and email-based communication.

Clinical Infectious Diseases (CID)
Volume 59 Issue 11 December 1, 2014
http://cid.oxfordjournals.org/content/current

Editor’s choice: Clinical and Laboratory Findings of the First Imported Case of Middle East Respiratory Syndrome Coronavirus to the United States
Minal Kapoor, Kimberly Pringle, Alan Kumar, Stephanie Dearth, Lixia Liu, Judith Lovchik, Omar Perez, Pam Pontones, Shawn Richards, Jaime Yeadon-Fagbohun, Lucy Breakwell, Nora Chea,
Nicole J. Cohen, Eileen Schneider, Dean Erdman, Lia Haynes, Mark Pallansch, Ying Tao, Suxiang Tong, Susan Gerber, David Swerdlow, and Daniel R. Feikin
Clin Infect Dis. (2014) 59 (11): 1511-1518 doi:10.1093/cid/ciu635
Abstract
The first US case of Middle East respiratory syndrome coronavirus was confirmed in May 2014 in a 65-year-old physician who worked in Saudi Arabia and presented to an Indiana hospital on illness day 11. He had bilateral pneumonia and recovered fully.

Editorial Commentary: Changing Epidemiology of Influenza B Virus
W. Paul Glezen
Author Affiliations
Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas
Extract
Influenza B virus is an important cause of acute respiratory illness that tends to be overlooked because of the prominence of influenza A. On average, influenza B is responsible for about 25% of laboratory-documented influenza. Morbidity is highest in schoolchildren, but all age groups are at risk [1]. Comparisons of the clinical presentation and complications for influenza A and B infections have shown little difference; infected children tend to be slightly older during influenza B epidemics and may be more likely to have myalgia or myositis [2]. The epidemiology of influenza B has changed over the past 30 years. From 1974 to 1985, 4 epidemics caused by influenza B viruses were observed in Houston, Texas [3]. These epidemics were relatively discreet and varied considerably in intensity. Younger schoolchildren aged 5–14 years had the highest attack rates, resulting in high rates of school absenteeism [4]. Observations through the influenza B/Hong Kong epidemic of 1976–1977 showed that 73% of the infections detected during the first one-third of the epidemic occurred in students 5–19 years of age. As the epidemic proceeded, the proportion of infections in schoolchildren dropped and proportions for preschool children and adults increased; this observation along with others supported the hypothesis that schoolchildren are the main spreaders of influenza in the community…

Development in Practice
Volume 24, Issue 8, 2014
http://www.tandfonline.com/toc/cdip20/current

Best practice for rural food security projects in Southern Africa?
Terry Leahy* & Monika Goforth
DOI:10.1080/09614524.2014.969196
pages 933-947
Abstract
It has been widely believed that commercialisation is the solution to food insecurity in rural Africa. Project designs have attempted to set up agricultural cooperatives and encourage entrepreneurial farmers. Yet the problems revealed in the 1950s are still widespread. In a counter-perspective, some have argued for the relevance of subsistence and low-input agriculture. This article examines three NGO projects in South and South-eastern Africa which prioritise food security through household subsistence, using low-input technologies, along with an encouragement to produce a surplus for cash. We look at what these projects share and why their strategies work.

A training approach for community maternal health volunteers that builds sustainable capacity
Cathy Green*, Miniratu Soyoola, Mary Surridge & Dynes Kaluba
DOI:10.1080/09614524.2014.957165
pages 948-959
Abstract
This article examines a training approach for community health volunteers which increased access to maternal health services in rural communities in Zambia. The effectiveness of the training approach was evaluated in an operations research component. Skilled birth attendance rates increased by 63% from baseline over a two-year period in the intervention districts, out-performing increases recorded in control sites at statistically significant levels. As a low-cost, high-impact intervention which shows good sustainability potential, the approach is suitable for national level scale-up and for adaptation for use in other countries in support of maternal and new-born health goals.

Coordinating post-disaster humanitarian response: lessons from the 2005 Kashmir earthquake, India
Peer Ghulam Nabi*
DOI:10.1080/09614524.2014.964187
pages 975-988
Abstract
This article is based on a field study carried out in Indian-administered Kashmir after the 2005 earthquake. In this analysis of how non-governmental development organisations (NGDOs) engage and coordinate with one another and with other disaster response agencies during post-disaster relief and rehabilitation operations, it can be concluded that NGDO coordination was ineffective. The research points out that, even though there is coordination among the international and national NGDOs, local NGDOs are seldom engaged in the overall coordination processes. The paper advocates developing coordination among the humanitarian agencies as a pre-disaster initiative for a more effective collaborative humanitarian disaster response.

Eurosurveillance
Volume 19, Issue 45, 13 November 2014
http://www.eurosurveillance.org/Public/Articles/Archives.aspx?PublicationId=11678

The Innovative Medicines Initiative launches call on Ebola and other filoviral haemorrhagic fevers
Eurosurveillance editorial
On 6 November 2014, the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) [1] launched its second Call for Proposals in the framework of the IMI2 ‘Ebola and other filoviral haemorrhagic fevers programme (the Ebola+ programme)’ [2]. Submissions for the Call can be made as of 22 November and closes on 1 December, and has an indicative budget of € 140 million.
The following topics are covered in the Call for proposals:
Topic 1: Vaccine development Phase I, II, and III
Topic 2: Manufacturing capability
Topic 3: Stability of vaccines during transport and storage
Topic 4: Deployment and compliance of vaccination regimens
Topic 5: Rapid diagnostic tests
The Call and its topics will be further explained in a 17 November webinar.

JAMA
November 12, 2014, Vol 312, No. 18
http://jama.jamanetwork.com/issue.aspx

Viewpoint | November 12, 2014
The Ebola Outbreak, Fragile Health Systems, and Quality as a Cure
Andrew S. Boozary, MD, MPP1; Paul E. Farmer, MD, PhD2; Ashish K. Jha, MD, MPH1,3,4
Author Affiliations
…CONCLUSIONS
Ebola represents a pressing global health crisis, but more are certain to follow. The outcomes of the next several months will reveal the capacity to forge effective partnerships across borders and disciplines, and the extent of the commitment to value all human lives equally. By responding to the crisis with a surge of stopgap solutions, it is possible (although unlikely) that such an approach could eventually stem the epidemic and end the morbidity and mortality for this current outbreak. Alternatively, responding to Ebola with a broader approach that involves meaningful investments in the provision of health care staff, resources, and systems could succeed now and help create sustainable models for the future. If the approach involves reengineering health systems around the patient, there remains an opportunity to bring lasting progress for those who need it most.

Original Investigation | November 12, 2014
Evaluation of the Association of Maternal Pertussis Vaccination With Obstetric Events and Birth Outcomes
Elyse O. Kharbanda, MD, MPH1; Gabriela Vazquez-Benitez, PhD1; Heather S. Lipkind, MD, MS2; Nicola P. Klein, MD, PhD3; T. Craig Cheetham, PharmD, MS4; Allison Naleway, PhD5; Saad B. Omer, PhD6; Simon J. Hambidge, MD, PhD7,8; Grace M. Lee, MD, MPH9,10; Michael L. Jackson, PhD11; Natalie L. McCarthy, MPH12; Frank DeStefano, MD, MPH12; James D. Nordin, MD, MPH1
Author Affiliations
JAMA. 2014;312(18):1897-1904. doi:10.1001/jama.2014.14825.
ABSTRACT
Importance In 2010, due to a pertussis outbreak and neonatal deaths, the California Department of Health recommended that the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) be administered during pregnancy. Tdap is now recommended by the Advisory Committee on Immunization Practices for all pregnant women, preferably between 27 and 36 weeks’ gestation. Limited data exist on Tdap safety during pregnancy.
Objective To evaluate whether maternal Tdap vaccination during pregnancy is associated with increased risks of adverse obstetric events or adverse birth outcomes.
Design and Setting Retrospective, observational cohort study using administrative health care databases from 2 California Vaccine Safety Datalink sites.
Participants and Exposures Of 123 494 women with singleton pregnancies ending in a live birth between January 1, 2010, and November 15, 2012, 26 229 (21%) received Tdap during pregnancy and 97 265 did not.
Main Outcomes and Measures Risks of small-for-gestational-age (SGA) births (<10th percentile), chorioamnionitis, preterm birth (<37 weeks’ gestation), and hypertensive disorders of pregnancy were evaluated. Relative risk (RR) estimates were adjusted for site, receipt of another vaccine during pregnancy, and propensity to receive Tdap during pregnancy. Cox regression was used for preterm delivery, and Poisson regression for other outcomes.
Results Vaccination was not associated with increased risks of adverse birth outcomes: crude estimates for preterm delivery were 6.3% of vaccinated and 7.8% of unvaccinated women (adjusted RR, 1.03; 95% CI, 0.97-1.09); 8.4% of vaccinated and 8.3% of unvaccinated had an SGA birth (adjusted RR, 1.00; 95% CI, 0.96-1.06). Receipt of Tdap before 20 weeks was not associated with hypertensive disorder of pregnancy (adjusted RR, 1.09; 95% CI, 0.99-1.20); chorioamnionitis was diagnosed in 6.1% of vaccinated and 5.5% of unvaccinated women (adjusted RR, 1.19; 95% CI, 1.13-1.26).
Conclusions and Relevance In this cohort of women with singleton pregnancies that ended in live birth, receipt of Tdap during pregnancy was not associated with increased risk of hypertensive disorders of pregnancy or preterm or SGA birth, although a small but statistically significant increased risk of chorioamnionitis diagnosis was observed.

The Lancet
Nov 15, 2014 Volume 384 Number 9956 p1721 – 1820
http://www.thelancet.com/journals/lancet/issue/current

Editorial
Feeding the world sustainably
The Lancet
Preview |
Good nutrition is fundamental to human health and wellbeing, yet according to the latest estimates from the UN Food and Agriculture Organization (FAO), about 805 million people—more than a tenth of the world’s population—remain chronically undernourished. In 2013, 161 million children younger than 5 years were affected by stunting, and 51 million by wasting. Undernourishment is the main underlying cause of death in this age group, accounting for 45% of child deaths worldwide. Meanwhile, more than 2 billion people are affected by deficiencies of micronutrients such as iodine, vitamin A, zinc, and iron.

Nature
Volume 515 Number 7526 pp163-304 13 November 2014
http://www.nature.com/nature/current_issue.html

Ethical dilemma for Ebola drug trials
Public-health officials split on use of control groups in tests of experimental treatments.
Erika Check Hayden
11 November 2014
With clinical trials of experimental Ebola treatments set to begin in December, public-health officials face a major ethical quandary: should some participants be placed in a control group that receives only standard symptomatic treatment, despite a mortality rate of around 70% for Ebola in West Africa?

Two groups planning trials in Guinea and Liberia are diverging on this point, and key decisions for both are likely to come this week. US researchers meet on 11 November at the National Institutes of Health (NIH) in Bethesda, Maryland, to discuss US-government sponsored trials. A separate group is gathering at the World Health Organization (WHO) in Geneva, Switzerland, on 11 and 12 November to confer on both the US effort and trials organized by the WHO with help from African and European researchers and funded by the Wellcome Trust and the European Union.

Experts convened by the WHO in August gave ethics approval to test experimental treatments amid the Ebola epidemic in West Africa. But the WHO trial organizers are not including control arms because most African patients treated with ‘standard of care’ — which includes fluid-replacement therapy, pain relief and drugs to ward off secondary infections — die. A trial in Guinea of ‘convalescent serum’, a blood product thought to include protective antibodies, will only assign a patient to a control group if there is no available serum matched to that person’s blood type.

“These trials will be conducted in a context of fear, distrust, a lack of effective care options, the admission of multiple family members to the same centre, and sometimes violence against health-care workers,” says Peter Horby, an epidemiologist at the University of Oxford, UK. “Scientific arguments cannot tell us what will work in these conditions.”

Organizers of the US-government-led trial disagree that every patient should receive experimental treatment, arguing that it will not necessarily be better than standard care. “The idea that there’s no need for randomized, controlled trials presupposes that the drugs have zero side effects, that they are efficacious, and that there’s no substantial variability from patient to patient,” says Clifford Lane, deputy director for clinical research and special projects at the US National Institute of Allergy and Infectious Diseases in Bethesda, Maryland. “I don’t think any of that is true.”

Several experimental interventions, including convalescent serum and the antibody cocktail ZMapp, have been given to patients in the United States, but they have been used at different stages of the disease. As a result, it is not clear whether the treatments improved patients’ outcomes.

That is one motivation for the upcoming US trial, which will be run among three treatment centres that have cared for people with Ebola: the NIH Clinical Center, Emory University in Atlanta, Georgia, and the University of Nebraska Medical Center in Omaha. “The idea is to talk about whether we might do this in a more systematic way at these three units,” Lane says. The NIH is in discussions with Liberian officials that may lead to a similar clinical trial there.

Both the US and WHO trials will use ‘adaptive’ designs that aim to determine quickly whether an intervention is effective. The US effort will probably employ a ‘master protocol’ to compare various treatments against a standard-of-care arm, says Edward Cox, director of the antimicrobial products division of the US Food and Drug Administration’s Center for Drug Evaluation and Research in Silver Spring, Maryland.

Officials at the two meetings this week will make decisions about which interventions to test on the basis of the limited evidence about potential benefits and side effects, drug availability, and ease of administration in West Africa. Some groups have moved ahead with trials of medications approved for other purposes; the non-profit medical-aid organization EMERGENCY, based in Milan, Italy, is planning to test the cardiac drug amiodarone at an Ebola treatment centre outside Freetown in Sierra Leone.

The choices about which drugs to test have been made more urgent by recent news that the Ebola epidemic may be waning in some regions, especially in Liberia. “There are going to be a limited number of places where you can actually do trials,” says Ripley Ballou, the head of Ebola vaccine research at GlaxoSmithKline’s vaccine division in Rixensart, Belgium. “It’s conceivable that there could be a backlog.”

But Piero Olliaro, head of intervention and implementation research on neglected tropical diseases at the WHO, does not think that this will pose a problem. Because Ebola is so deadly, he says, a treatment’s efficacy can be determined by testing it on as few as 100–150 people. “Patients are dying every day that we spend debating these issues,” he says. “We all share already the responsibility of not having answered these questions before the epidemic, so that we could have started studies right from the beginning.”

Nature | Comment
Infectious disease: Tough choices to reduce Ebola transmission
Christopher J. M. Whitty, Jeremy Farrar, Neil Ferguson, W. John Edmunds, Peter Piot, Melissa Leach & Sally C. Davies
06 November 2014
Christopher J. M. Whitty and colleagues explain why the United Kingdom is funding many small community centres to isolate suspected cases in Sierra Leone.

New England Journal of Medicine
November 13, 2014 Vol. 371 No. 20
http://www.nejm.org/toc/nejm/medical-journal

Original Article
Effects of Vaccination on Invasive Pneumococcal Disease in South Africa
Anne von Gottberg, M.B., B.Ch., Ph.D., Linda de Gouveia, N.D., M.T., Stefano Tempia, D.V.M., Ph.D., Vanessa Quan, M.B., B.Ch., M.P.H., Susan Meiring, M.B., Ch.B., Claire von Mollendorf, M.B., B.Ch., Shabir A. Madhi, M.B., B.Ch., Ph.D., Elizabeth R. Zell, M.Stat., Jennifer R. Verani, M.D., M.P.H., Katherine L. O’Brien, M.D., M.P.H., Cynthia G. Whitney, M.D., M.P.H., Keith P. Klugman, M.B., B.Ch., Ph.D., and Cheryl Cohen, M.B., B.Ch. for the GERMS-SA Investigators
N Engl J Med 2014; 371:1889-1899 November 13, 2014 DOI: 10.1056/NEJMoa1401914
Abstract
Background
In South Africa, a 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in 2009 with a three-dose schedule for infants at 6, 14, and 36 weeks of age; a 13-valent vaccine (PCV13) replaced PCV7 in 2011. In 2012, it was estimated that 81% of 12-month-old children had received three doses of vaccine. We assessed the effect of vaccination on invasive pneumococcal disease.
Methods
We conducted national, active, laboratory-based surveillance for invasive pneumococcal disease. We calculated the change in the incidence of the disease from a prevaccine (baseline) period (2005 through 2008) to postvaccine years 2011 and 2012, with a focus on high-risk age groups.
Results
Surveillance identified 35,192 cases of invasive pneumococcal disease. The rates among children younger than 2 years of age declined from 54.8 to 17.0 cases per 100,000 person-years from the baseline period to 2012, including a decline from 32.1 to 3.4 cases per 100,000 person-years in disease caused by PCV7 serotypes (−89%; 95% confidence interval [CI], −92 to −86). Among children not infected with the human immunodeficiency virus (HIV), the estimated incidence of invasive pneumococcal disease caused by PCV7 serotypes decreased by 85% (95% CI, −89 to −79), whereas disease caused by nonvaccine serotypes increased by 33% (95% CI, 15 to 48). Among adults 25 to 44 years of age, the rate of PCV7-serotype disease declined by 57% (95% CI, −63 to −50), from 3.7 to 1.6 cases per 100,000 person-years.
Conclusions
Rates of invasive pneumococcal disease among children in South Africa fell substantially by 2012. Reductions in the rates of disease caused by PCV7 serotypes among both children and adults most likely reflect the direct and indirect effects of vaccination. (Funded by the National Institute for Communicable Diseases of the National Health Laboratory Service and others.)

PLoS One
[Accessed 15 November 2014]
http://www.plosone.org/

Sporozoite Immunization of Human Volunteers under Mefloquine Prophylaxis Is Safe, Immunogenic and Protective: A Double-Blind Randomized Controlled Clinical Trial
Else M. Bijker, Remko Schats, Joshua M. Obiero, Marije C. Behet, Geert-Jan van Gemert, Marga van de Vegte-Bolmer, Wouter Graumans, Lisette van Lieshout, Guido J. H. Bastiaens, Karina Teelen, Cornelus C. Hermsen, Anja Scholzen, Leo G. Visser, Robert W. Sauerwein
Research Article | published 14 Nov 2014 | PLOS ONE 10.1371/journal.pone.0112910

A New Recombinant BCG Vaccine Induces Specific Th17 and Th1 Effector Cells with Higher Protective Efficacy against Tuberculosis
Adeliane Castro da Costa, Abadio de Oliveira Costa-Júnior, Fábio Muniz de Oliveira, Sarah Veloso Nogueira, Joseane Damaceno Rosa, Danilo Pires Resende, André Kipnis, Ana Paula Junqueira-Kipnis
Research Article | published 14 Nov 2014 | PLOS ONE 10.1371/journal.pone.0112848

Research Article
Perception of Human Papillomavirus Infection, Cervical Cancer and HPV Vaccination in North Indian Population
Showket Hussain, Vilas Nasare, Malasha Kumari, Shashi Sharma, Mohammad Aijaz Khan mail, Bhudev C. Das, Mausumi Bharadwaj mail
Published: November 11, 2014
DOI: 10.1371/journal.pone.0112861
Abstract
Background
Human Papillomavirus (HPV) -associated cervical cancer is the second-most common cancer in women worldwide but it is the most frequent gynaecological cancer and cancer associated death in India women. The objective of this study was to assess knowledge about cervical cancer, HPV, HPV vaccine, HPV vaccine acceptance among school and undergraduates students and their parent’s perception about acceptance of HPV vaccine in Northern part of India (Delhi and NCR regions).
Materials and Methods
A qualitative questionnaire based survey among 2500 urban/rural students aged 12–22 years was conducted.
Results
Overall, a low frequency (15%) of HPV and cervical cancer awareness was observed in students and their parents. However, the awareness was much higher in females belonging to urban setup compared to boys with a perception that HPV causes cervical cancer in women only. Additionally, only (13%) participants who were aware of cervical cancer and HPV) were willing to accept HPV vaccination. Apparently, parents of female students were two times more willing to accept HPV vaccination for their ward than male students (p<0.001; OR 95%CI = 2.09 (1.58–2.76).
Conclusion
Cervical cancer and HPV awareness among school, undergraduate students and also to their parents was found to be very low in this part of India. The level of awareness and education appears to be insignificant determinants in rural compared to urban setup. Better health education will be needed to maximize public awareness for cervical cancer prevention.

PLoS Neglected Tropical Diseases
(Accessed 15 November 2014)
http://www.plosntds.org/

Review
The Global One Health Paradigm: Challenges and Opportunities for Tackling Infectious Diseases at the Human, Animal, and Environment Interface in Low-Resource Settings
Wondwossen A. Gebreyes mail, Jean Dupouy-Camet, Melanie J. Newport, Celso J. B. Oliveira, Larry S. Schlesinger, Yehia M. Saif, Samuel Kariuki, Linda J. Saif, William Saville, Thomas Wittum, Armando Hoet, Sylvain Quessy, Rudovick Kazwala, [ … ], Lonnie J. King , [ view all ]
Published: November 13, 2014
DOI: 10.1371/journal.pntd.0003257
Abstract
Zoonotic infectious diseases have been an important concern to humankind for more than 10,000 years. Today, approximately 75% of newly emerging infectious diseases (EIDs) are zoonoses that result from various anthropogenic, genetic, ecologic, socioeconomic, and climatic factors. These interrelated driving forces make it difficult to predict and to prevent zoonotic EIDs. Although significant improvements in environmental and medical surveillance, clinical diagnostic methods, and medical practices have been achieved in the recent years, zoonotic EIDs remain a major global concern, and such threats are expanding, especially in less developed regions. The current Ebola epidemic in West Africa is an extreme stark reminder of the role animal reservoirs play in public health and reinforces the urgent need for globally operationalizing a One Health approach. The complex nature of zoonotic diseases and the limited resources in developing countries are a reminder that the need for implementation of Global One Health in low-resource settings is crucial. The Veterinary Public Health and Biotechnology (VPH-Biotec) Global Consortium launched the International Congress on Pathogens at the Human-Animal Interface (ICOPHAI) in order to address important challenges and needs for capacity building. The inaugural ICOPHAI (Addis Ababa, Ethiopia, 2011) and the second congress (Porto de Galinhas, Brazil, 2013) were unique opportunities to share and discuss issues related to zoonotic infectious diseases worldwide. In addition to strong scientific reports in eight thematic areas that necessitate One Health implementation, the congress identified four key capacity-building needs: (1) development of adequate science-based risk management policies, (2) skilled-personnel capacity building, (3) accredited veterinary and public health diagnostic laboratories with a shared database, and (4) improved use of existing natural resources and implementation. The aim of this review is to highlight advances in key zoonotic disease areas and the One Health capacity needs.

Achieving Population-Level Immunity to Rabies in Free-Roaming Dogs in Africa and Asia
Michelle K. Morters mail, Trevelyan J. McKinley, Daniel L. Horton, Sarah Cleaveland, Johan P. Schoeman, Olivier Restif, Helen R. Whay, Amelia Goddard, Anthony R. Fooks, I. Made amriyasa,
James L. N. Wood
Published: November 13, 2014
DOI: 10.1371/journal.pntd.0003160
Abstract
Canine rabies can be effectively controlled by vaccination with readily available, high-quality vaccines. These vaccines should provide protection from challenge in healthy dogs, for the claimed period, for duration of immunity, which is often two or three years. It has been suggested that, in free-roaming dog populations where rabies is endemic, vaccine-induced protection may be compromised by immuno-suppression through malnutrition, infection and other stressors. This may reduce the proportion of dogs that seroconvert to the vaccine during vaccination campaigns and the duration of immunity of those dogs that seroconvert. Vaccination coverage may also be limited through insufficient vaccine delivery during vaccination campaigns and the loss of vaccinated individuals from populations through demographic processes. This is the first longitudinal study to evaluate temporal variations in rabies vaccine-induced serological responses, and factors associated with these variations, at the individual level in previously unvaccinated free-roaming dog populations. Individual-level serological and health-based data were collected from three cohorts of dogs in regions where rabies is endemic, one in South Africa and two in Indonesia. We found that the vast majority of dogs seroconverted to the vaccine; however, there was considerable variation in titres, partly attributable to illness and lactation at the time of vaccination. Furthermore, >70% of the dogs were vaccinated through community engagement and door-to-door vaccine delivery, even in Indonesia where the majority of the dogs needed to be caught by net on successive occasions for repeat blood sampling and vaccination. This demonstrates the feasibility of achieving population-level immunity in free-roaming dog populations in rabies-endemic regions. However, attrition of immune individuals through demographic processes and waning immunity necessitates repeat vaccination of populations within at least two years to ensure communities are protected from rabies. These findings support annual mass vaccination campaigns as the most effective means to control canine rabies.
Author Summary
Canine-mediated rabies is a horrific disease that claims tens of thousands of human lives every year, particularly in Asia and Africa. The disease can be effectively controlled through mass vaccination of dogs with high-quality vaccines; however, questions remain over the effectiveness of vaccination where the health status of free-roaming dogs may be compromised and the life expectancy and access to these dogs may be limited. This study evaluated rabies-vaccine induced immune responses and vaccine delivery in previously unvaccinated, free-roaming dog populations in two rabies endemic regions in Asia and Africa, to better understand the effectiveness of vaccination campaigns. We found that the majority of dogs seroconverted to the vaccine regardless of health status. Excellent vaccination coverage was achieved through community engagement and door-to-door vaccine delivery, even where the majority of the dogs needed to be caught by net for vaccination. However, attrition of immune individuals through demographic processes and waning immunity reinforces the importance of frequent and regular vaccination campaigns to ensure effective vaccination coverage is maintained.

Vaccine
Volume 32, Issue 50, Pages 6725-6866 (28 November 2014)
http://www.sciencedirect.com/science/journal/0264410X/32/50

Integration of vaccine supply chains with other health commodity supply chains: A framework for decision making
Review Article
Pages 6725-6732
Prashant Yadav, Patrick Lydon, Julianna Oswald, Modibo Dicko, Michel Zaffran
Abstract
One of the primary objectives of National Immunization Programs is to strengthen and optimize immunization supply chains so that vaccines are delivered to the end recipients effectively, efficiently and sustainably. As a result of larger investments in global health and a wider portfolio of vaccines, global agencies are recognizing the need for vaccine supply chains to operate at their most optimal levels. Integration with other supply chains is often presented as a strategy to improve efficiency. However, it remains unclear if the proposed benefits from integration of vaccine supply chains with other supply chains will outweigh the costs. This paper provides a framework for deciding where such integration offers the most significant benefits. It also cautions about the pitfalls of integration as a one size fits all strategy. It also highlights the need for systematic collection of cost and efficiency data in order to understand the value of integration and other such initiatives.

Parental attitudes and decision-making regarding MMR vaccination in an anthroposophic community in Sweden – A qualitative study
Original Research Article
Pages 6752-6757
Emma Byström, Ann Lindstrand, Nathalie Likhite, Robb Butler, Maria Emmelin
Abstract
Measles outbreaks occur regularly throughout Europe, up to 31 500 cases in the previous year, particularly where there are pockets of populations with lower vaccination coverage than the recommended ≥95%. Anthroposophic communities in Europe are one of several groups with relatively low vaccination coverage. In Sweden, outbreaks of measles and rubella were reported from an anthroposophic community. Thus the aim of this qualitative study was to explore facilitators and barriers to MMR vaccination among parents living in anthroposophic communities in Sweden. Twenty parents living in an anthroposophic community were interviewed, focusing on their views and decisions on MMR vaccination. The interviews were analyzed using qualitative content analysis. Two overarching views of health emerged, differentiating broadly parents who vaccinate vs. parents who do not vaccinate. Four themes describing parental attitudes toward measles vaccination were developed and three of these, the conformers, the pragmatists and the attentive delayers describe different approaches toward vaccinations among those who actually vaccinate. The last theme, promoters of natural immunity, represents those postponing or refusing vaccination beyond childhood. This study suggests that there is a spectrum of parental beliefs regarding MMR vaccination in this anthroposophic community. Interventions specifically targeted to the anthroposophic community and strengthening health workers capacity for a constructive dialog on vaccine’s benefit and risks may contribute to higher vaccination coverage. This is believed to minimize the risk of future epidemics and contribute to the WHO European Region’s goal of eliminating measles.

History of Vaccinology
Interwoven support: An historical survey of US federal programs enabling immunization
Original Research Article
Pages 6855-6866
Dack W. Dalrymple, John D. Grabenstein
Abstract
Highlights
:: US Government involvement with immunization begins with events in 1777 and 1813.
:: Involvement accelerated upon licensing of manufacturing quality in 1903.
:: Military and civilian programs help discover and develop new vaccines.
:: USG programs funded vaccine purchases and delivered and supported vaccinations.
:: USG programs help assess safety, compensate after injury, and protect workers.

Vaccines — Open Access Journal
(Accessed 15 November 2014)
http://www.mdpi.com/journal/vaccines
Review
A Systematic Review of Recent Advances in Equine Influenza Vaccination
by Romain Paillot
published 14 November 2014

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

AIDS and Clinical Research
2015, 5:11
[PDF] Trial, Error, and Breakthrough: A Review of HIV Vaccine Development
Sheila M Barry*, Alfredo J Mena Lora and Richard M Novak
Division of Infectious Diseases, Immunology and International Medicine, Department of Medicine, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA
Abstract
With more than 35 million infected in over thirty years, the HIV pandemic has been a unique challenge to the scientific community. The development of effective anti-retroviral therapy has decreased morbidity and mortality of those infected with HIV, but a comprehensive approach that includes effective prevention strategies will be needed to curb this unique pandemic. Vaccines remain the best option, but the development of a safe and effective preventive HIV vaccine has defied decades of research. Over 30 products have been tested in more than 85 trials, but no safe and effective vaccine has been developed yet. Despite these setbacks, these decades of research have broadened the understanding of HIV immunopathogenesis and closer to the goal of a successful HIV vaccine. In 2009, a prime-boost vaccine demonstrated an efficacy of 31.2%. This trial, RV144, signaled hope for the future and served as proof of concept that an effective HIV-1 vaccine is possible. Understanding the unique obstacles in HIV vaccine development has been key in creating breakthroughs and tracing a path forward. The complexity of this challenge has required innovative approaches to vaccine development. Future HIV preventive vaccine candidates may target multiple immune pathways. Strategies such as cytotoxic vaccines, envelope targets and antibodies such as broadly neutralizing antibodies or monoclonal antibodies may work in concert to achieve protection from HIV acquisition. An effective HIV preventive vaccine is ever near.

Media/Policy Watch

BBC
http://www.bbc.co.uk/
Accessed 15 November 2014
14 November 2014
Polio eradication programme reaches ‘major milestone’
By James Gallagher Health editor, BBC News website
A “major milestone” in the battle to eliminate polio globally has been reached, the US Centres for Disease Control (CDC) has said.
Its experts think a second of the three forms of poliovirus has been eliminated after mass vaccination campaigns.
Wild poliovirus type 3 has not been detected for more than two years. Type 2 was eradicated in 1999…
…Prof Walt Orenstein, from the vaccine centre at Emory University in the US, told the BBC: “Type 3 appears to be gone – I think it is overwhelmingly likely that we are there, but it’s too soon to say we’re definitely there.
“So it’s not a total victory, but it is very promising.”
But he warned: “Pakistan is a major concern, about 85% of wild type 1 poliovirus this year has been in Pakistan, but in Nigeria there is real hope we can get rid of type 1 even by the end of this year.”…

Brookings
http://www.brookings.edu/
Accessed 15 November 2014
November 13, 2014 4:17pm
USAID Administrator Rajiv Shah: Ebola “One of the Toughest Challenges We Face”
Yesterday, Brookings hosted a discussion on the current state of the Ebola crisis, with USAID Administrator Rajiv Shah; Eric Postel, assistant to the USAID administrator for Africa; and a panel of Brookings experts plus Oscar Bloh, the chairperson of the Civil Society Organization Ebola Response Taskforce, Liberia and also country director, Search for Common Ground Liberia. Listen to the complete audio here. The administrator’s opening remarks are presented below (edit some for clarity).
The Ebola Crisis: U.S. Leadership and International Response Listen to Audio play

Council on Foreign Relations
http://www.cfr.org/
Accessed 15 November 2014
Transcript
Ebola Update
with Helene D. Gayle, Stephen S. Morse, Jordan S. Kassalow November 10, 2014
Experts discuss international efforts to combat the Ebola outbreak in West Africa.

DEVEX
https://www.devex.com/en/
Global Views – Inside Development
Moving beyond access to development — immunization reframed
By Robert Steinglass12 November 2014
…In the immunization field, there is growing recognition that in addition to vaccine accessibility there are serious challenges such as availability of vaccination services; awareness of when and where to get vaccinated; acceptability of vaccination and understanding its benefits; affability of services; agency of women to leave home and seek services; affordability for parents to use services and for the health system to provide them; and accountability of the program to community, government and funding agencies….

The Economist
http://www.economist.com/
Accessed 15 November 2014
15 November 2014
Treating Ebola – Unchained malady
What is the best way to test drugs and vaccines for Ebola fever?
EVERY year, in early November, researchers gather at a conference called TropMed to discuss tropical diseases. This year it was New Orleans’s turn to host them, and, not surprisingly, the meeting was dominated by Ebola—specifically, how to develop and test treatments for it in a timely and ethical manner.
American and European Ebola patients have been treated with experimental drugs that include an antiviral agent called brincidofovir; a mixture of synthetic antibodies called ZMapp; extracts of serum from recovered patients; and a medicine called TKM-Ebola which interferes with viral replication. Yet without some kind of trial it is impossible to say that any of these worked. Survival rates have been higher than in Africa, but no one knows whether this is the result of the treatment or of better supportive care.
Such trials are now planned. On November 12th Médicins sans Frontières (MSF), a charity at the forefront of dealing with Ebola, announced it was hosting three—of brincidofovir, of serum, and of another drug, favipiravir—in its treatment facilities in Liberia and Guinea. But supportive care clearly matters, too. Billy Fischer, of the University of North Carolina School of Medicine, told TropMed that providing intravenous hydration to every patient at the centre in Guinea at which he worked reduced mortality rates from 74% to less than 50%. Dr Fischer thinks that, with the proper resources, it would be possible to get the rate down to 20%.
One aspect of trials that particularly concerned TropMed was what are known as control arms. These are the parts of a trial that set the benchmark a drug or vaccine must beat to prove that it is effective. One way to create a control arm is to pick some of the volunteers at random and give them not the new treatment, but the best existing one. For a disease as lethal and lacking in existing treatments as Ebola, though, that is regarded by many as unethical, since it denies some participants a possibly life-saving medicine.
One way to ameliorate that problem is to design a trial to be “adaptive”, meaning data from it are assessed as they accumulate. If a drug seems effective early on in a trial, those in the control group can then be offered it immediately. In the case of Ebola, however, Edward Cox, director of the office of microbial products at America’s Food and Drug Administration has proposed another modification to normal procedure. He told TropMed that his organisation, in collaboration with the National Institutes of Health (NIH), has devised a way to compare several drugs at once against a single control group, greatly reducing the number of patients needed to act as controls.
Sometimes, nature herself provides a control arm. In the serum trial announced by MSF, immune-system compatibility problems mean not everyone can be injected with a given serum. The trial’s organisers, the Antwerp Institute of Tropical Medicine, therefore hope (with the permission of those involved) to use people who cannot be injected as their controls.
In the case of the other two trials, though, this approach is not possible. Instead, they will do what Dr Fischer did and compare the efficacy of their treatments with mortality rates at the clinics concerned before the trials started.
At least one other approach is possible, too. This is called a “step-wedge” design and will be used by another American government organisation, the Centres for Disease Control and Prevention (CDC), in a vaccine trial being run in Sierra Leone. A lack of people and equipment in west Africa means it is not possible to vaccinate everyone at once. The CDC’s researchers hope to make a virtue of this unfortunate fact, and assess the vaccine’s efficacy by comparing infection rates in groups vaccinated at different times.
Which approach will work best remains to be seen. But there may be a moral dilemma for ethicists if trials whose control arms put volunteers at risk turn out to be the quicker way to an answer. For every day that passes without decent drugs and a vaccine means Ebola kills more people.

The Guardian
http://www.guardiannews.com/
Accessed 15 November 2014
14 November 2014
David Cameron presses for indemnities to speed Ebola vaccinations
Global response to crisis criticised by Britain at G20 summit as it calls for more funding and faster licensing of medicines
…The indemnity fund would protect pharmaceutical companies developing new drugs that might subsequently turn out to have side-effects, but need to be licensed urgently.
GlaxoSmithKline’s chief executive, Andrew Witty, said an indemnity system was required because companies were being urged by the World Health Organisation to fast-track novel vaccines in months rather than years.
There is currently no proven vaccine against Ebola and drug companies have been wary of investing in the area since the commercial opportunity is small. Potential losses or claims arising from the use of new vaccines would represent an additional hurdle.
Many drug companies are now discussing ways to help with production, including some such as Pfizer that are not directly involved in Ebola vaccine development but believe they could provide technical expertise.
It has been argued that, out of necessity, some drugs are being developed in five months that would traditionally undergo five years of checks.
The companies have been lobbying Downing Street to give them financial protection so some of the drawn out licensing programme can be short-circuited. Different trials are due to start next year in Liberia, Sierra Leone and Guinea.
Speaking in Brisbane before the G20 summit began, Jim Yong Kim, the World Bank president, said the global response to Ebola in Africa was still not enough as the crisis was still not under control in Sierra Leone and Guinea.
“I’m encouraged especially by the tremendous response of both the United States and the UK. But I would still say that despite the pledges and the goodwill that has been expressed, we still need much, much more commitment,” he said.
To offer protection against the threat posed by future pandemics to the global economy, the World Bank has proposed setting up a fund that could disburse millions and possibly billions of dollars in aid.
“What we’re talking about is almost like an insurance policy that when the World Health Organisation declared a global health emergency, when they invoked what’s called the International Health Regulations, then and only then would this fund disburse,” Kim said.
“The idea is that we have funds to protect from other kinds of downside risks to the global economy. I just want to stress that pandemics, epidemics, are in fact very real downside risks to the global economy.
“If we had a flu pandemic that would move very quickly and potentially kill millions, we would need many billions disbursed right away.”

New York Times
http://www.nytimes.com/
Accessed 15 November 2014
Researchers to Test New Treatments in Countries Hit Hardest by ...
Nov. 12, 2014 – By ANDREW POLLACK
Although there are currently no drugs or vaccines approved in the United States to treat or prevent Ebola, health officials have used several …

Reuters
http://www.reuters.com/
Exclusive: MSF should have called for Ebola vaccine earlier, says aid group veteran
By Daniel Flynn and Robert-Jan Bartunek
DAKAR/BRUSSELS Fri Nov 14, 2014 1:10am EST
(Reuters) – Medecins Sans Frontiers “wasted time” by waiting too long to call for vaccines to fight an unprecedented outbreak of Ebola in West Africa, a veteran of the medical charity told Reuters.
The group’s response to the epidemic which has so far killed more than 5,000 people has been widely praised by governments and the World Health Organization. While Western donors dithered and other aid groups pulled out, MSF deployed hundreds to the Ebola “hot zones” and treated more than 3,000 patients.
But the emergency group relied too much on strategies it developed during smaller previous eruptions of the virus, leading it to make mistakes as this year’s rampant multi-country epidemic pushed it to its limits, said Jean-Herve Bradol, a member of MSF’s internal think-tank.
“Our response was too orientated toward the management of previous outbreaks,” Bradol, of the Paris-based Centre For Reflection on Humanitarian Action (CRASH), told Reuters, adding that MSF’s public appeal for vaccine development in September came months too late.
“We wasted time before speaking about a vaccine and treatments… It’s very hard to imagine controlling this epidemic now without a vaccine.”…

Wall Street Journal
http://online.wsj.com/home-page?_wsjregion=na,us&_homepage=/home/us
Accessed 15 November 2014
Dengue Fever Researchers in Military Weigh Infecting Volunteers
11/13/14
U.S. military scientists are considering resurrecting a research program that would infect healthy people with dengue fever, the potentially deadly mosquito-borne disease that has no known drug treatment.
Ebola workers ask Congress for help
11/12/14
WASHINGTON — A top U.S. official outlined plans Wednesday for clinical trials of a possible Ebola vaccine in West Africa, as the global response to the outbreak took on added urgency with the disclosure of a new cluster of cases in Mali and reports that the death toll had surpassed 5,000.
Federal Goal Is to Vaccinate 80% of Boys and Girls Against HPV by 2020
11/10/14
With oral-cancer rates climbing for men, federal health authorities are looking to overcome parental qualms and achieve 80% HPV vaccination rates of boys and girls by 2020.

Vaccines and Global Health: The Week in Review is a weekly digest — summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.
.
– pdf version:  A pdf of the current issue is available here:  Vaccines and Global Health_The Week in Review_8 November 2014

– blog edition: comprised of the 35+ entries posted below on 28 September 2014

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.
.
– Support:  If you would like to join the growing list of individuals who support this service and its contribution to their roles in public health, clinical practice, government, IGOs/NGOs, research, industry and academia, please visit this page at The Wistar Institute, our co-founder and fiduciary. Thank you…

.
.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy
a program of the
– Division of Medical Ethics, NYU Medical School
– The Wistar Institute Vaccine Center
– Children’s Hospital of Philadelphia Vaccine Education Center
Associate Faculty, Division of Medical Ethics, NYU Medical School

POLIO [to 8 November 2014]
Public Health Emergency of International Concern (PHEIC)

GPEI Update: Polio this week – As of 22 October 2014
Global Polio Eradication Initiative
Editor’s Excerpt and text bolding
Full report: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx
:: Two new cases of circulating vaccine derived polio virus (cVDPV) have been reported in South Sudan, constituting an outbreak. Immunization activities are planned in November and December in order to stop the spread of cVDPV.
:: Immunization campaigns in Iraq in September reached 88% of children under 5. Around 20 million children were vaccinated across the Middle East in October. These activities are helping to protect the gains made against the virus in the region, with no case reported for nearly 7 months.
:: In central Africa, it has been 6 months since the latest case of polio in Equatorial Guinea. In Cameroon, high level delegates from the World Health Organization, UNICEF and the Center for Disease Control and Prevention met with the Prime Minister and the Minister of Health in order to discuss the urgency of the outbreak response
Afghanistan
:: Six new wild poliovirus type 1 (WPV1) cases were reported in the past week in Afghanistan. Of these, 4 are from Kandahar province (2 in Kandahar district, and 1 in each of the previously uninfected districts of Shahwalikot and Arghandab); 1 is from the Bermel district of Paktika province, and 1 from the previously uninfected province of Ghazni, in Giro district. The most recent case had onset of paralysis on 4 October in Arghandab district, Kandahar province. The total number of WPV1 cases is now 18.
:: Given the growing outbreak in neighbouring Pakistan, Afghanistan is taking protective steps to limit any spread of the virus. Subnational Immunization Days (SNIDs) are scheduled across the south and east of Afghanistan 16-18 November using bivalent oral polio vaccine (OPV).
Nigeria
:: One new type 2 circulating vaccine-derived poliovirus (cVDPV2) case was reported in the past week in Bindawa district of Katsina province. The total number of cVDPV2 cases for 2014 is now 21. This cVDPV2 case had onset of paralysis on 12 September.
Pakistan
:: Fifteen new wild poliovirus type 1 (WPV1) cases were reported in the past week in Pakistan. Of these, 8 are from the Federally Administered Tribal Areas (FATA) (1 from South Waziristan, 1 from Frontier Region Bannu and 6 from Khyber Agency); 3 from Balochistan province (2 from Killa Abdullah district and 1 from Quetta); and 4 from Khyber Pakhtunkhwa (KP) province (3 from Peshawar district and 1 from Charsada district, previously uninfected in 2014). The most recent case had onset of paralysis on 20 October in South Waziristan. This brings the total number of WPV1 cases in 2014 to 235 compared to 56 in 2013 by this date.
:: Immunization activities are continuing with particular focus on known high-risk areas, in particular the newly opened areas of FATA. At exit and entry points of areas that are inaccessible during polio campaigns, 163 permanent vaccination points are being used to reach internally displaced families as they move in and out of the inaccessible area. Over 700,000 people have been vaccinated in the past few months at transit points and in host communities, including half a million children.
Horn of Africa
:: Two new cases of circulating vaccine derived poliovirus type 2 (cVDPV2) have been reported in South Sudan this week. Both are from Rubkona district of Unity province. The most recent onset of paralysis was on the 12 September.
West Africa
:: Even as polio programme staff across West Africa support efforts to control the Ebola outbreak affecting the region, efforts are being made in those countries not affected by Ebola to vaccinate children against polio. National Immunization Days (NIDs) are planned in Benin, Burkina Faso, Cape Verde, Côte d’Ivoire, Gambia, Ghana, Mauritania, Senegal and Togo starting 31 October and in Guinea Bissau starting on 8 November. Subnational Immunization Days (SNIDs) will also take place starting 31 October in Niger and Mali.

FINAL COMMUNIQUE: EXTRAORDINARY SESSION OF THE AUTHORITY OF ECOWAS HEADS OF STATE AND GOVERNMENT
ECOWAS – Economic Community of West African States
N°: 204/2014
6 NOVEMBER 2014 [Accra, Ghana]
[Excerpts; Editor’s text bolding]
5. The Summit was deeply concerned by the negative impact of the Ebola Virus Disease on the economies of the countries directly affected, human security as well as the social and humanitarian situation in the region. It equally expressed concern regarding the threat to the regional integration process as well as regional peace and security posed by this epidemic.
6. The Authority expressed strong feelings at the loss of thousands of lives since the outbreak of the epidemic and reiterated solidarity and sympathy with the people of the affected countries, in particular Guinea, Liberia, Nigeria, Sierra Leone and Mali.
7. The Heads of State and Government reaffirmed their firm commitment to continue their joint and coordinated efforts in the determined fight against the Ebola Virus Disease. To that end, they commended the appropriate actions undertaken by Nigeria and Senegal, which enabled these two Member States to contain the epidemic. While also encouraging the other affected countries in their efforts to contain the epidemic, they expressed their hope that these countries will achieve the same success.
8. In the same vein, with a view to ensuring the efficiency of all the efforts, the Authority appointed E. Faure Essozimna Gnassingbe President of the Togolese Republic to supervise the Ebola Virus Disease response and eradication process.
9. Furthermore, after endorsing the Regional Integrated Operational Plan for Response to the Ebola Virus Disease and welcoming the relevance of the areas of intervention contained therein, the Heads of State and Government made the following specific decisions:

To the Member States
10. The Heads of State and Government call on all the Member States to urgently develop and implement guidelines on Ebola treatment and management in line with WHO standards. They also urge them to join ICAO and seek assistance from the ICAO/WHO Cooperation Arrangement for the Prevention of the Spread of Communicable Diseases through Air Travel (CAPSCA).
11. In addition, Authority urges the Member States to contribute military personnel and logistics to enhance response capacities, support the medical staff on the field and participate in the construction of additional treatment and isolation centres as well as ensure their security. It also encourages Member States to provide additional medical and voluntary staff to the affected countries.
12. The Summit commends the Member States that made contributions to the Regional Solidarity Fund to fight Ebola mainly Benin, Burkina Faso, Cote d’Ivoire, Mali, Niger, Nigeria, Senegal and Sierra Leone and urges the other countries to fulfill their commitment to the Fund.
13. The Heads of State and Government reiterate their unwavering commitment to the principles of free movement within the ECOWAS region and invite all the Member States to adhere to them, in particular by removing restriction and ban on the movement of persons and goods to and from the affected countries, while observing the appropriate health control at the borders.
14. The Authority urges the Member States to conduct extensive public education, communication and awareness on the Ebola Virus Disease with a view to preventing the stigmatisation of affected persons and stopping the transmission of the disease.
15. To better address sanitary crisis in the future, the Heads of State and Government consider that it is essential to ensure the strengthening of national health systems by improving upon their effectiveness and also by increasing the resources allocated them in the national budgets in accordance with the Abuja Declaration, which requires the allocation of 15% of the total budget.

To the ECOWAS Commission
16. The Heads of State and Government reiterate the need to strengthen the regional multi-sectoral coordination in the fight against the epidemic and underpin the important role of ECOWAS in that regard.
17. To that end, the Authority requests the Commission to take the necessary measures, in collaboration with of all the stakeholders and persons involved in the field, to mobilise adequate resources for the coordinated implementation of the Regional Operational Plan for Response to the Ebola Virus Disease.
18. The Authority directs the Commission to actively participate in the various actions undertaken to support the efforts of the Member States particularly in the planning, implementation and coordination of all United Nations Mission for Ebola Emergency Response (UNMEER) and African Union activities in the region. The Authority also instructs the Commission to create a consultation framework with the Mission for a short, medium and long-term response.
19. The Summit directs the Commission to support Member States to better coordinate their medical and humanitarian efforts on the field.
20. The Authority instructs the Commission to take all the necessary actions to set up a regional center for disease prevention and control in West Africa and enhance health research in West Africa. It also encourages the Commission to be involved in the ongoing initiatives towards the development of vaccines.
21. Authority requests the Commission to deepen the socio-economic and cultural assessment of the epidemic and take all necessary steps to provide the appropriate medium and long term response through a resolute action against poverty and ignorance, for sustainable growth and development.

22. To the International Community, the Heads of State and Government welcome the adoption of the United Nations Resolution 2177, which marks its unanimous determination to eradicate the Ebola Virus Disease.
23. In that regard, the Authority commends the show of international solidarity in support to the efforts of the affected countries. In particular, it welcomes the technical and financial support from all the ECOWAS bilateral and multilateral partners on the field.
24. In view of the continuing and increasing challenges of the Ebola Virus Disease, the Summit calls on all the partners to maintain the level of their commitment and support to the region, in particular by increasing their financial assistance to the affected Member States.
25. Similarly, the Summit invites private sector, civil society, regional and international humanitarian and development organizations to intensify efforts in technical, financial and institutional assistance to support treatment centers and other regular medical facilities in the affected countries, as well as public education, awareness and communication.
26. The Authority also invites all the relevant Partners to accelerate efforts for vaccines and adequate therapy against the virus as well as support the region in the development of research capacity. In addition, Authority calls on them to prioritise the provision of vaccines at subsidized prices to the affected countries, and to the region.
27. The Heads of State and Government call on all the airlines and maritime companies to continue flight schedules to the affected countries or resume operations notably to transport health and humanitarian goods, drugs and equipment. They also call on partner countries to lift the restrictions on visa issuance to nationals of affected countries.
28. The Authority decides to remain seized of the situation of the epidemic in West Africa and directs the President of the Commission to ensure the implementation of adopted decisions and regularly provide updates on the epidemic…

WHO: Ebola Virus Disease (EVD)
Situation report – 5 November 2014 ‘WHO Roadmap’
HIGHLIGHTS
:: There have been 13,042 reported cases of Ebola, with 4818 reported deaths, up to the end of 2 November.
:: All districts in Liberia and Sierra Leone have been affected.
:: All 83 contacts of the health-care worker infected in Spain have completed 21-day follow-up
[Excerpt from Summary]
…At the country level, the weekly incidence appears to be stable in Guinea. In Sierra Leone the weekly incidence continues to rise, while in Liberia it appears to be declining. In all three countries, EVD transmission remains persistent and widespread, particularly in the capital cities. All administrative districts in Liberia and Sierra Leone have reported at least 1 confirmed or probable case of EVD since the outbreak began. Cases and deaths continue to be under-reported in this outbreak.
Of the countries with localized transmission, Mali and the United States of America continue to monitor potential contacts. In Spain, all 83 contacts of the health-care worker infected in Madrid have completed the 21-day follow-up period.

WHO welcomes approval of a second Ebola vaccine trial in Switzerland
Statement
6 November 2014
WHO welcomes approval by Swissmedic, the Swiss regulatory authority for therapeutic products, of a second Swiss trial of an experimental Ebola vaccine. The trial will be led by the University Hospitals of Geneva (HUG). If judged safe, larger scale trials will be taken to African countries as early as January 2015.
This trial approval means that the vaccine will be tested on approximately 115 volunteers in Geneva. The trial, which is receiving support from WHO, is the latest in a series of trials involving 2 different candidate Ebola vaccines that are ongoing in Switzerland, Mali, the United Kingdom, and the United States.
About the vaccine
The experimental VSV-ZEBOV vaccine has been developed by scientists at the Public Health Agency of Canada . It is based on the virus that causes vesicular stomatitis, a disease affecting animals. This virus has been weakened and genetically modified to express the glycoprotein of the Zaire Ebola virus (ZEBOV) so as to provoke an immune response against real Ebola viruses.
The experimental vaccine will be tested on healthy volunteers, some of whom will be deployed as health care staff in the fight against the Ebola epidemic in West Africa. The trial will test the safety of the vaccine and its ability to provoke an immune response. VSV-ZEBOV is also being tested on healthy volunteers in the USA (the first trial started 13 October) and trials are planned to start very soon in Germany, Gabon and Kenya.
Vaccine trials
The trial is the second one organised in Switzerland and coordinated by WHO. The first vaccine, “ChAd3″ – Chimpanzee-Adenovirus ChAd3-ZEBOV – started trials in Lausanne at the end of October….

WHO: African regulators’ meeting looking to expedite approval of vaccines and therapies for Ebola
November 2014
Aiming to make potential Ebola therapies and vaccines available as quickly as possible, the ninth African Vaccine Regulatory Forum (AVAREF), taking place in Pretoria, South Africa, from 3-7 November, will devote the first two days to agree on a collaborative mechanism for fast tracking approvals for clinical trials and registration of these products in the affected countries.
“As the President of Liberia has aptly put, the best cure for Ebola is stronger health systems,”
said Kees De Joncheere, WHO Director for Essential Medicines and Health products.
“It is crucial that we match the speed with which Ebola vaccines are being developed and tested with equal haste in making them available to populations once they are judged safe and effective,” said Sarah Barber, WHO Representative in South Africa. “To do that, we need to agree on the design of clinical trials, and we need to collaborate across borders to fast-track scientific assessment, regulatory approval and roll-out.”
The mechanism would cover:
:: Clear pathways and timelines for expedited ethical and regulatory review of clinical trial applications and approval of products;
:: Agreement on timelines and joint safety and efficacy assessments of the new products to fast-track national registration;
:: Endorsement of a panel of safety experts for expedited review of safety data of new products with relevant communication to National Regulatory Authorities (NRAs);
:: Technical assistance from the World Health Organization (WHO) to facilitate these processes.
Ebola, which has killed close to 5 000 people so far and crushed the already weakened health systems of Guinea, Liberia and Sierra Leone, had until recently received little attention from the pharmaceutical sector. The current outbreak, unprecedented in geographical scope and severity, has mobilised numerous private and public stakeholders to accelerate the development of vaccines to contain the outbreak and prevent other such crises in the future.
Three vaccines are currently undergoing human safety trials outside Africa. Once they are judged safe, further trials will take place in the countries affected by Ebola. The vaccines are being developed respectively by Glaxo-Smith-Kline with the US Government, Johnson & Johnson, and the Canadian Public Health Agency.
At the same time, partnerships between WHO and some member states are looking to the plasma of Ebola survivors, who have built antibodies to the virus, as a possible therapeutic option for people who are already infected. The plasma clinical trials will also need expedited review by ethics committees and regulators. If judged safe and effective, this therapy can be rolled out rapidly.
The Pretoria meeting will bring together public health officials, regulatory and industry experts from 25 African countries and international health stakeholders. The meeting has awakened broad interest among African governments because the accelerated mechanism fast track process it will put in place could be used as a model for other countries to accelerate access to potentially useful therapies in emergency situations.
“As the President of Liberia has aptly put, the best cure for Ebola is stronger health systems,” said Kees De Joncheere, WHO Director for Essential Medicines and Health products. “That wake-up call could turn things around for Africa and represent another step towards increasing access to and better regulation of health products,
AVAREF
AVAREF was founded in 2006 by WHO to support NRAs in making informed decisions concerning authorization of clinical trials, evaluation of product registration dossiers, and any other challenging issues related to vaccines evaluation. AVAREF provides African regulatory authorities charged with ensuring the safety of medical products and related research with expertise and opportunities for information sharing and capacity building. It also offers product developers the opportunity for joint review by regulatory authorities from multiple countries of clinical trial and marketing authorization applications for high priority vaccines to be used in African countries. While initially focused on vaccines, AVAREF is beginning to expand to cover medicines and diagnostics as well.

WHO Guidance: How to conduct safe and dignified burial of a patient who has died from suspected or confirmed Ebola virus disease
October 2014 :: 17 pages
WHO/EVD/Guidance/Burials/14.2
Download the full version in English
Overview
This protocol provides information on the safe management of dead bodies and burial of patients who died from suspected or confirmed Ebola virus disease.
These measures should be applied not only by medical personnel but by anyone involved in the management of dead bodies and burial of suspected or confirmed Ebola patients.
Twelve steps have been identified describing the different phases Burial Teams have to follow to ensure safe burials, starting from the moment the teams arrive in the village up to their
:: Read the note for media

WHO: Ebola situation assessments
:: New study sheds light on the importance of supportive care for Ebola patients 6 November 2014

WHO IN ACTION
:: Government of Senegal boosts Ebola awareness through SMS campaign
3 November 2014

Related News on Ebola
:: Statement from the Travel and Transport Task Force on Ebola virus disease outbreak in West Africa 7 November 2014
WHO does not recommend general bans on travel or trade
Leading international organizations and associations from the transport, trade and tourism sector stand firmly with WHO against general bans on travel and trade, as well as restrictions that include general quarantine of travellers from Ebola-affected countries.
The Travel and Transport Task Force, established in August 2014, calls for international cooperation of governments and the transport sector in following the recommendations of the International Health Regulations Emergency Committee on Ebola, convened by WHO.
WHO does not recommend general bans on travel or trade, or general quarantine of travellers arriving from Ebola-affected countries, as measures to contain the outbreak.
Such measures can create a false impression of control and may have a detrimental impact on the number of health care workers volunteering to assist Ebola control or prevention efforts in the affected countries. Such measures may also adversely reduce essential trade, including supplies of food, fuel and medical equipment to the affected countries, contributing to their humanitarian and economic hardship….
…About the Travel and Transport Task Force
Members of the Travel and Transport Task Force include the World Health Organization (WHO), the International Civil Aviation Organization (ICAO), the World Tourism Organization (UNWTO), Airports Council International (ACI), International Air Transport Association (IATA), World Travel and Tourism Council (WTTC) International Maritime Organization (IMO), the International Chamber of Shipping (ICS) and the Cruise Lines International Association (CLIA).
:: WHO welcomes strong commitment from Australia to beating Ebola
6 November 2014

WHO – African Region
:: Dr Matshidiso Moeti of Botswana nominated new World Health Organization’s Regional Director for Africa
Cotonou, Benin, 5 November 2014 – Dr Matshidiso Moeti of the Republic of Botswana was today nominated to be the next World Health Organization’s Regional Director for Africa.
Health Ministers from the 47 Countries that constitute the WHO African Region nominated her at their annual meeting, which is taking place in Cotonou. Dr Moeti is scheduled to take up her new post on 1 February 2015, succeeding Dr Luis Sambo, whose mandate ends on 31 January 2015 after having served as the Regional Director for the past 10 years.
Speaking after her nomination, she pledged to work for and with every member state to address the health challenges facing the African Region. The Regional Director-elect noted that the Millennium Development Goals propelled the Region to a certain level of health. Dr Moeti also underscored the need to further work to enhance equity and human rights towards universal health care. “I commit myself and colleagues to build on what we have created so far and I am confident that we will ride on the positive things happening in the Region.”
Dr Moeti’s nomination is subject to confirmation by WHO’s Executive Board in January 2015.

More News
:: Dr Sambo urges countries to accelerate the progress of implementation of the African Public Health Emergency Fund – 06 November 2014

:: African countries resolve to step up efforts to tackle vaccine preventable diseases – 05 November 2014

:: Dr Sambo proposes key actions to tackle Ebola – 05 November 2014

:: President Boni Yayi urges African leaders to strengthen health systems to contain epidemics – 03 November 2014

WHO Director-General addresses the Regional Committee for Africa
http://www.who.int/dg/speeches/2014/regional-committee-africa/en/
Dr Margaret Chan
Director-General of the World Health Organization
Address to the Regional Committee for Africa, Sixty-fourth Session
Cotonou, Republic of Benin
3 November 2014
[Full text]
Excellencies, honourable ministers, distinguished delegates, representatives of the African Union, Dr Sambo, ladies and gentlemen,

Many external experts and analysts believe that Africa is at a crossroads. As I speak to you, Africa shows the world two prominent public faces that are strikingly different.
One face shows Africa rising, undergoing an economic and social transformation that is unparalleled in any other region of the world, at any time in recent history.

This is the face that showcases Africa’s abundant natural resources, its increasingly educated, peaceful, and healthy populations, and the region’s resilience, creativity, and boundless energy.

This is the face of beginnings: of prosperity, wellbeing, and a healthy future. But this bright future depends on whether governments make equity in the distribution of benefits an explicit policy goal.

As the latest Progress Panel and Report on Africa, headed by Kofi Annan, notes: “The ultimate measure of progress in Africa is not to be found in GDP numbers and growth rates, but in the wellbeing of people, and in prospects for enabling people to improve their lives.”

As you all know, much of Africa’s growth has been concentrated in sectors, such as mining and petroleum, that favour the elite but do little to improve living conditions and health status in the rural areas where most of the poor and sick reside.

All nations benefit from an Africa that is prosperous, stable, and fair. This view was underscored in September during an emergency session of the UN Security Council, which considered the Ebola outbreaks in West Africa as a threat to international security.

In Guinea, Liberia, and Sierra Leone, Ebola has set back hard-won political stability and economic recovery, and is reversing some striking recent gains in health outcomes.
Let me give you just one statistic to think about. In 2012, WHO estimated that 21 000 people, 95% of them children, died of malaria in the three West African countries combined.

This figure was a marked improvement over the 34 000 malaria deaths estimated for 2000. This is just one of many positive trends that is now under threat.

Ladies and gentlemen,
The Ebola outbreak that is ravaging parts of West Africa is the most severe acute public health emergency seen in modern times. It has many unprecedented dimensions, including its heavy toll on frontline domestic medical staff.

I extend my deepest sympathy to the people of West Africa who have seen so many of their fellow countrymen fall ill and die. I extend my deepest sympathy to the families, the loved ones, the neighbours, and entire villages and communities.

I can tell you one thing: every one of these West Africans who died from Ebola was beloved.

All of us must respect the compassion and courage of so many health workers who unselfishly risked their lives, and lost them. The three countries have lost some of their greatest humanitarian heroes.

In the midst of these alarming trends, two WHO arguments that have fallen on deaf ears for decades are now out there with consequences that all the world can see, every day, on prime-time TV news.

The first argument concerns the urgent need to strengthen long-neglected health systems, an argument long-championed by your RD [Regional Director].

When heads of state in non-affected countries talk about Ebola, they rightly attribute the outbreak’s unprecedented severity to the “failure to put basic public health infrastructures in place.”

Without fundamental public health infrastructures in place, no country is stable. No society is secure. No resilience exists to withstand the shocks that our 21st century societies are delivering with ever-greater frequency and force, whether from a changing climate or a runaway killer virus.

The second argument is this. Ebola emerged nearly four decades ago. Why are clinicians still empty-handed, with no vaccines and no cure?

Because Ebola has historically been confined to poor African nations. The R&D incentive is virtually non-existent. A profit-driven industry does not invest in products for markets that cannot pay. WHO has been trying to make this issue visible for ages. Now people can see for themselves.

Ladies and gentlemen,

I will leave it to an African medical correspondent to comment on the two faces of today’s Africa.

He has written eloquently about how outbreaks of diseases, like Ebola, make Africa’s neglected health systems and impoverished populations highly visible.

He cites the importance of the recent economic transformation to Africa’s international reputation as a continent of hope. But he is quick to ask the related question. “What good does it do,” he asks, “to cover the ceiling of your house with golden paint when the walls and foundation have cracks?”
I will end my Ebola comments here.

You have a heavy agenda to get through. You need to approve a regional strategic plan for immunization, with highly ambitious targets. Like the rest of the world, you will be transitioning from the Millennium Development Goals to a post-2015 development agenda.

Africa needs to seize this new agenda on its own terms. Frankly, this region has, in the past, suffered from some bad development advice.

Future solutions to Africa’s problems must be uniquely African solutions. In the past, Africa has followed in line with the priorities and strategies defined by global health initiatives, and not always as defined by your own governments and perceived health needs. Now Africa needs to lead.

In April, African ministers of health, at their gathering in Luanda, endorsed universal health coverage as a means to achieve and sustain the health MDGs and recognized it as an essential part of the post-2015 development agenda. This is what I mean by leadership.

Among the items on your agenda is the nomination of your next regional director.

I thank Dr Luis Sambo for his years of dedication to WHO and to the health of the African people. I wish him every success as he opens a new chapter in his long career.
For this Regional Office, the next big challenge is to ensure that WHO reform is credible and efficient.

Thank you.

UNMEER [UN Mission for Ebola Emergency Response] @UNMEER #EbolaResponse
UNMEER’s website is aggregating and presenting content from various sources including its own External Situation Reports, press releases, statements and what it titles “developments.” We present a composite below from the week ending 8 November 2014.

UNMEER External Situation Reports
UNMEER External Situation Reports are issued daily (excepting Saturday) with content organized under these headings:
– Highlights
– Key Political and Economic Developments
– Human Rights
– Medical
– Logistics
– Outreach and Education
– Resource Mobilisation
– Essential Services
– Upcoming Events
The “Week in Review” will present highly-selected elements of interest from these reports. The full daily report is available as a pdf using the link provided by the report date.

7 November 2014
Highlights
Key Political and Economic Developments
1. UN Special Envoy on Ebola Dr. David Nabarro said the extraordinary global response over the past month has made him hopeful the outbreak could end in 2015, though he cautioned that the fight to contain the disease is not even a quarter done. In the past four weeks, the rate of EVD infections seems to be slowing in some parts of West Africa, he said. In other hotspots it appears to be expanding the way it was a month ago. Nabarro said there are five times more beds for treatment in the three most affected countries than there were two months ago, which is helping to reduce the number of cases, along with improving efforts to find infected people and trace their contacts. Nabarro pointed to two other positive signs: the extraordinary global response in the last month and the mobilization of local communities in the three countries as a result of massive media campaigns and house-to-house “sensitization efforts” involving traditional leaders.
Response Efforts and Health
5. The EVD outbreak has likely killed far more people than the 4,828 deaths reported by the World Health Organization, WHO’s strategy chief Christopher Dye said Thursday, warning that thousands of fatalities were likely not accounted for. The likely explanation is that many people are burying the dead in secret, possibly to avoid having authorities interfere with burial customs like washing and touching the deceased, which is widely blamed for much of the transmission. The fact that WHO-reported numbers of cases and deaths are lower now than they were last week is due a different, more consistent manner of counting, Mr. Dye said. It does not imply a slowing down of the disease.
8. As part of the Rapid Response Team, UNICEF recently conducted rapid assessments of “hot spots” in Liberia – namely Grand Kru, Grand Bassa, Sinoe and Grand Cape Mount counties – focused on how to rapidly isolate and treat patients with symptoms of Ebola following clear infection control standards. The process involves working with County Health Teams, communities and partners to design local solutions including the setup of Community Care Centers, providing technical assistance on water, sanitation and hygiene management, and advising on how to engage communities. Additional assessments in Gbarpolu and Bomi are underway.
Essential Services
16. Sierra Leone’s Deputy Health Minister Madina Radman said the country’s failure to clearly separate its EVD treatment units from regular health facilities had destroyed confidence in hospitals and clinics. “We are struggling to regain confidence in our health facilities because of this mistake”, she said. “About 50 per cent of the deaths in the country are not Ebola but, because people fear to come to some of our healthcare facilities, they die needlessly due to other treatable diseases.”
17. According to analysis by the ngo Action Contre la Faim and the University of Naples Federico II, in 2015 the EVD crisis will lead to an increase of people suffering from undernourishment in Guinea, Liberia and Sierra Leone. 5,3 to 5,7 million people are expected be undernourished in 2015 in the 3 most affected countries, compared to 5 million before the start of the epidemic.

6 November 2014
Key Political and Economic Developments
1. The International Finance Corporation (IFC), a member of the World Bank Group, announced a package of at least 450 million USD in commercial financing that will enable trade, investment, and employment in Guinea, Liberia and Sierra Leone. The private sector initiative will include 250 million USD in rapid response projects, and at least 200 million USD in investment projects to support post-epidemic economic recovery. It is part of the World Bank Group’s effort to support the most affected countries during the Ebola Virus Disease (EVD) epidemic and prepare them for economic recovery.
3. The Obama administration will ask the US Congress for about 6.2 billion USD in emergency funding to combat the spread of EVD in West Africa and reduce risks for U.S. citizens. According to a statement from the US Office of Management and Budget, the money would be used to strengthen domestic public health systems, contain and mitigate the outbreak in West Africa, and speed up efforts to obtain vaccines. The request seeks 2.4 billion USD for domestic public health services. Another 2.1 billion USD is for the US State Department and its Agency for International Development, 112 million USD for the Pentagon and 1.5 billion USD to be put in a contingency fund.
Human Rights
7. Sierra Leone said Wednesday it was holding a journalist in a maximum security prison after a guest on his radio show criticised President Ernest Bai Koroma’s handling of the Ebola outbreak. David Tam Baryoh, host of the weekly “Monologue” programme on the private radio station Citizen FM, was arrested on Tuesday and sent to Freetown’s Pademba Road jail. Baryoh had interviewed an opposition party spokesman who criticised Koroma and his government’s handling of the Ebola outbreak.
Response Efforts and Health
9. The International Federation of Red Cross and Red Crescent Societies (IFRC), the lead agency managing burials and cremations, estimates that of all EVD deaths, 87% (4,404 of 5,060 cumulative deaths) have been managed by a trained burial or cremation team. A limitation of this estimation is that a significant number of deaths and burials are not reported, and that is does not yet include burials managed by other organizations. WHO estimates there is a need for 528 trained burial teams in the three affected countries. Currently 140 trained teams are on the ground.

5 November 2014
Key Political and Economic Developments
1. World Bank President Jim Yong Kim on Tuesday urged Asian countries to send trained health workers to the West African countries hit by Ebola Virus Disease (EVD), warning the focus on stricter border control was not the solution. He welcomed efforts by South Korea, China and Japan to send medical personnel or equipment to combat the outbreak. Asia must send more medical teams to the three affected countries, he said, adding that just 30 medical teams from around the world have gone to assist in the countries so far.
4. Residents in Wonkifong, Guinea, approximately 90 km from Conakry demonstrated yesterday against the establishment of a new EVD treatment unit in their locality; security forces intervened to restore calm. Negotiations are underway to resolve the situation.
Response Efforts and Health
7. Australia is contracting a private company to staff and operate an EVD treatment unit in Sierra Leone, Prime Minister Tony Abbot has said. He said Australia would commit 17m USD to a 100-bed treatment unit being built by the UK. But he ruled out sending government health workers – most workers would be hired locally with international staff likely to include some Australians.
10. As of last week, 110 UNICEF-supported social and mental health workers had provided psychosocial, family tracing, reunification and reintegration support to 817 children affected by EVD in Liberia’s ten most affected counties. In addition, UNICEF is working with the Liberian government to train EVD survivors to care for these children and be engaged in community mobilization activities.
Essential Services
18. FAO, WFP, governments and other partners are currently carrying out a Crops and Food security Assessment Mission (CFSAM) based on rapid joint assessments in the field in Guinea, Liberia and Sierra Leone. The mission will provide an analysis of the agricultural production, prices, markets, trades and stocks situation. The first outcomes should be available before 18 November 2014.

4 November 2014
Key Political and Economic Developments
4. Dr. Peter Salama, Global Ebola Emergency Coordinator for UNICEF, told reporters at UN Headquarters that the agency will be doubling its staff from 300 to 600 in the three most-affected countries – Guinea, Liberia and Sierra Leone – where children account for one-fifth of all Ebola cases. Dr. Salama also said an estimated 5 million children are affected and some 4,000 children have become orphaned from the current epidemic. UNICEF is reaching out to EVD survivors who are often willing to work on the frontlines of the disease response at the community level in local care centers with community health workers.
Human Rights
6. In Dandayah, in the Forécariah prefecture of Guinea, a group of contact tracers was chased away by residents under threat of death, despite appeals for calm by several officials including the mayor.
Resource Mobilisation
1. The African Union (AU) is seeking funding from some of the continent’s richest people, including several billionaires, to pay the costs for volunteer doctors and nurses fighting EVD in West Africa, it said yesterday. The bloc is seeking to raise $35 million in the first round and eventually as much as $100m for the Business-to-Rescue Fund. A separate campaign to ask for contributions from citizens will follow.
Essential Services
11. The peak season for Lassa fever in West Africa is about to begin. The virus has been largely forgotten in the EVD crisis, and health workers are warning that they may not have the resources to deal with the disease if cases increase. The symptoms of Lassa are largely identical to EVD, posing an extra problem. All of the countries worst hit by EVD are home to Lassa fever.

3 November 2014
Human Rights
6. According to a survey by UNICEF, 96 percent of Ebola survivors in Sierra Leone have experienced some sort of discrimination. More than three-quarters of respondents told UNICEF they would not welcome back an Ebola survivor into their community.
Essential Services
20. Women are no longer giving birth in health facilities due to EVD. Contraception distributions have also dropped by 70 per cent leading to fears of a high rate of new teenage pregnancies and a doubling of severe acute malnutrition of children under five with mothers struggling to earn money for food. Indeed, new data on severe acute malnutrition admissions in Liberia for the month of September 2014 revealed that a total of 325 severely malnourished children under the age of five were admitted to UNICEF-supported integrated management of acute malnutrition treatment sites.
21. MSF has begun distributing antimalarial medicines in Monrovia, Liberia, a crucial medical
intervention in a city where the basic health care system has collapsed in recent months. Malaria is endemic in Liberia but due to the incredible demand of the EVD outbreak on the medical system, basic health care such as malaria treatment is now very difficult to find in Monrovia. MSF’s program will prevent new malaria cases and minimize the number of people with malaria at EVD treatment units. US philanthropist Bill Gates on Sunday announced he will donate over USD 500 million to fight malaria.

2 November 2014 | Weekly Situational Analysis
6. EVD survivors and health workers in the affected countries regularly report being shunned by their communities. While some EVD survivors have been branded as witches for surviving the disease, members of burial teams have faced calls for eviction from their homes. The latter is all the more worrying as a study by the Yale School of Public Health this week found that the greatest impact in terms of the EVD response would come from ensuring safe burials: if transmission via burial practices were eliminated, it is assessed that the secondary infection rate would drop below one per EVD case.

UNMEER site: Press Releases
:: WFP Continues Scaling Up Ebola Response With Partners:“Together We Must Do More” (6 November 2014)

UNICEF [to 8 November 2014]
http://www.unicef.org/media/media_71724.html

:: Massive UNICEF shipments of supplies to fight Ebola reach 3,000MT mark
GENEVA/COPENHAGEN/NEW YORK, 7 November 2014 – UNICEF has sent almost 3,000 metric tonnes of life-saving supplies including protective equipment and essential medicine in the past three months to fight the spread of Ebola in Guinea, Liberia and Sierra Leone. The children’s agency is among the largest source of supplies in the Ebola response.

CDC/MMWR Watch [to 8 November 2014]
http://www.cdc.gov/media/index.html

:: CDC Increasing Supply of Ebola-specific Personal Protective Equipment for U.S. Hospitals – Press Release – Friday, November 7, 2014

:: Chikungunya outbreak progresses in Caribbean, Central and South America – Press Release – Thursday, November 6, 2014

:: Millions of US women are not getting screened for cervical cancer – Press Release – Wednesday, November 5, 2014

MMWR November 7, 2014 / Vol. 63 / No. 44::
– Declines in Pneumonia Hospitalizations of Children Aged <2 Years Associated with the Use of Pneumococcal Conjugate Vaccines — Tennessee, 1998–2012
-. Establishment of a Community Care Center for Isolation and Management of Ebola Patients — Bomi County, Liberia, October 2014

Obama seeks $6.2 billion for Ebola fight
By Associated Press November 5
WASHINGTON — President Barack Obama on Wednesday asked Congress for $6.2 billion in emergency funds to confront Ebola at its source in West Africa and to secure the United States against any possible spread.
Of the total, $2 billion would be apportioned to the United States Agency for International Development and $2.4 billion would go to the Department of Health and Human Services, the White House said. More than $1.5 billion would be for a contingency fund to deal with any unanticipated developments like a flare-up in West Africa or a need to vaccinate U.S. health care workers.
The Ebola money is the first request from Obama in the aftermath of an election that ushered in a Republican-controlled Congress, which is being seen as a repudiation of the president. The Ebola crisis has received bipartisan attention amid concerns over the potential of the disease to spread into the United States.
The White House is asking for prompt action, meaning it wants approval during the current lame duck session, while Democrats are still in control of the Senate. It wants the money on an “emergency” basis, meaning it should be added to the deficit. Republicans, if they agree the money is needed, may press for spending cuts elsewhere in the budget…

US officials unveil plan to test Ebola drugs
By Associated Press November 5
NEW ORLEANS — The quest for an Ebola treatment is picking up speed. Federal officials have unveiled a plan to test multiple drugs at once, in an umbrella study with a single comparison group to give fast answers on what works.
“This is novel for us” and is an approach pioneered by cancer researchers, said Dr. Luciana Borio, head of the U.S. Food and Drug Administration’s Ebola response. “We need to learn what helps and what hurts” and speed treatments to patients, she said.
She outlined the plan Wednesday at an American Society of Tropical Medicine and Hygiene conference in New Orleans. Thousands of scientists have crowded into day and late-night sessions on Ebola, which has killed 5,000 West Africans this year.
There is no treatment for Ebola, but several experimental ones such as ZMapp have been tried on a few patients, and scientists are eyeing some others that were developed for different conditions but may also fight Ebola.
“There’s this tremendous urge to want to give people these experimental therapies” but it’s crucial to make sure they don’t do harm, said the FDA’s Dr. Edward Cox.
Everyone in the umbrella study would get supportive care, such as intravenous fluids, then be assigned to receive one of several drugs or be in a comparison group. That’s needed because without one, there’s no way to know if any problems or deaths are from the drug or the disease, Cox said.
Instead of waiting until a certain number of patients are treated to look at results, as is usually done, researchers will monitor results as they come in, pairing each person on a drug with someone from the comparison group to see if a pattern can be detected.
The National Institutes of Health developed this “learn as you go” plan “to allow a winner to be declared very early,” Cox said.
He said the FDA could not name the drugs being considered, but said a meeting next week with various companies should crystallize the plans.

Thousands break Ebola quarantine to find food [Sierra Leone]
Associated Press | 4 November 2014
By SARAH DiLORENZO
DAKAR, Senegal (AP) — Thousands of people in Sierra Leone are being forced to violate Ebola quarantines to find food because deliveries are not reaching them, aid agencies said.
Large swaths of the West African country have been sealed off to prevent the spread of Ebola, and within those areas many people have been ordered to stay in their homes.
The government, with help from the U.N.’s World Food Program, is tasked with delivering food and other services to those people. But there are many “nooks and crannies” in the country that are being missed, Jeanne Kamara, Christian Aid’s Sierra Leone representative, said Tuesday…
…While public health authorities have said heavy restrictions may be necessary to bring under control an Ebola outbreak unlike any other, the Disasters Emergency Committee, an umbrella organization for aid organizations, warned on Monday that they were cutting off food to thousands of people.
“The quarantine of Kenema, the third largest town in Sierra Leone, is having a devastating impact on trade — travel is restricted so trucks carrying food cannot freely drive around,” the committee said in a statement. “Food is becoming scarce, which has led to prices increasing beyond the reach of ordinary people.”
Because services are not reaching them, people who are being monitored for signs of Ebola — and should be staying at home — are venturing out to markets to look for food, potentially contaminating many others, said Kamara of Christian Aid…

WHO & Regionals [to 8 November 2014]
:: GIN October 2014 pdf, 2.21Mb 4 November 2014

:: Global Alert and Response (GAR) – Disease Outbreak News (DONs)
Middle East respiratory syndrome coronavirus (MERS-CoV) – Saudi Arabia 7 November 2014

:: Weekly Epidemiological Record (WER) for 7 November 2014, vol. 89, 45 (pp. 505–508) includes:
– Report of the 7th Meeting of the WHO working group on polymerase chain reaction protocols for detection and subtyping of influenza viruses, Geneva, June 2014
http://www.who.int/entity/wer/2014/wer8945.pdf?ua=1

:: PPP launched to improve prevention of women’s cancers and quality of cancer registries in Latin America and the Caribbean
04 NOVEMBER 2014,
– PAHO (Pan American Health Organization) Foundation and International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) combine efforts to improve breast and cervical cancer prevention and control.
– The partnership aims to improve understanding and practices among primary health care providers and patients for breast cancer screening and early detection as well as increase capacity of cancer registries in the region.
– Three-year joint project is receiving $600,000 funding from IFPMA as well as in-kind contributions such as communications and infrastructure supplies.
New York, 4 November 2014 – The PAHO (Pan American Health Organization) Foundation and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) announced today a partnership to jointly build regional capacity to fight woman’s cancers in Latin America and the Caribbean. The three-year collaboration will allow the first phase of a $5M initiative to focus on women’s cancers in selected countries in Latin America and the Caribbean. …

GAVI Watch [to 8 November 2014]
http://www.gavialliance.org/library/news/press-releases/

:: Pentavalent vaccine introductions represent historic milestone for immunisation in India
01 November 2014
Rollouts in Madhya Pradesh and Rajasthan start two-phase process which will add 5-in-1 vaccine to routine immunisation programmes in every Indian state.

IVI Watch [to 8 November 2014]
http://www.ivi.org/web/www/home

:: EDCTP-TDR Clinical Research and Development Fellowships
IVI is pleased to announce its participation as a host organization for the EDCTP-TDR Clinical Research and Development Fellowships. EDCTP and the World Health Organization’s TDR have a partnership to support junior to mid-career researchers and clinical staff from low- and middle-income countries (LMICs) to develop new skills in clinical research and development through fellowship placements in pharmaceutical companies, PDPs and other relevant host organizations for up to two years. IVI has agreed to host two fellowship placements. Selected fellows will be placed at the institute for a minimum of six months and up to a maximum of 24 months. The Call for Proposals is currently open and the application deadline is 30 January 2015, 16:00 (GMT). For more information about the fellowships and how to apply, please visit: http://www.edctp.org/calls-and-grants/calls-for-proposals-overview/edctp-tdr-clinical-research-and-development-fellowships/

PATH Watch [to 8 November 2014]
http://www.path.org/news/

:: Announcement | November 03, 2014
PATH to collaborate with GlaxoSmithKline to develop a test critical to malaria care
New diagnostics for a common enzyme deficiency will bolster malaria elimination efforts

BMGF – Gates Foundation Watch [to 8 November 2014]
http://www.gatesfoundation.org/Media-Center/Press-Releases

:: Gates Foundation Commits More than $500 Million to Tackle The Burden of Infectious Disease in Developing Countries
[Excerpt]
NEW ORLEANS (November 2, 2014) – Calling the Ebola epidemic a “critical moment in the history of global health,” Bill Gates, Co-chair of the Bill & Melinda Gates Foundation, today urged greater investment in scientific innovation to ensure that the world stays ahead of rapidly evolving disease threats such as drug-resistant malaria and dengue fever.
Addressing the 63rd annual meeting of the American Society of Tropical Medicine and Hygiene, Gates announced that the foundation is committing more than $500 million in 2014 to reduce the burden of malaria, pneumonia, diarrheal diseases, and an array of parasitic infections that are leading causes of death and disability in developing countries. Gates also announced that the foundation has boosted its annual funding for malaria by 30 percent, and he laid out a vision for how malaria can be eradicated by the middle of the 21st century.
Gates said important lessons from the Ebola epidemic must guide the world’s response to all infectious diseases, particularly the need to strengthen health systems in developing countries, improve infectious disease surveillance systems and sustain investments in the R&D pipeline.
“The Ebola epidemic has shown, once again, that in today’s interconnected world, health challenges anywhere create health challenges everywhere – and the best way to overcome those challenges is to dedicate ourselves to the great cause of reducing the global burden of infectious disease,” Gates said in his prepared remarks.
On September 10, the foundation announced a $50 million commitment to support the scale up of efforts to contain the Ebola outbreak in West Africa. This funding – which is in addition to the more than $500 million announced today – will support emergency response efforts for Ebola, including capacity building and the establishment of Emergency Operations Centers in affected countries. The foundation is also supporting research on Ebola interventions, including rapid diagnostics, vaccines and ZMapp, an experimental Ebola treatment.

:: GAIA Vaccine Foundation’s Story-Telling Cloth gets “Innovation” Award For West African-Style “Social Media” Cervical Cancer Prevention Campaign
PROVIDENCE, R.I., Nov. 6, 2014 /PRNewswire/ — The Bill and Melinda Gates Foundation awarded $100,000 to GAIA Vaccine Foundation to test whether dissemination of a printed cloth that tells the story of HPV and cervical cancer, coupled with a media campaign led by influential women musicians, will improve HPV knowledge and incite women to be screened for cervical cancer and (when vaccine is available) to vaccinate their daughters against HPV in West Africa.. Cervical cancer is one of the most common and lethal cancers (67% mortality) among women in Africa, with rates that are approximately 5 fold higher than in the US. Nine out of ten (87%) cervical cancer deaths occur in less developed regions of the world, like Mali. This exceptionally high rate of cervical cancer is almost entirely due to lack of knowledge about HPV, since at least in Mali, cervical cancer screens are free and available at every health center.
Gates Foundation is funding the innovative idea that story-telling ‘Pagnes’, a traditional cloth worn by most women in West Africa, can motivate women to be screened for cancer while making use of fashion to disseminate cervical cancer education…

Industry Watch [to 8 November 2014]
Selected media releases and other selected content from industry.
:: The New England Journal of Medicine Publishes Results of Final Landmark Phase III Efficacy Clinical Study of Sanofi Pasteur’s Dengue Vaccine Candidate
– Study successfully met primary objective and confirms high efficacy against severe dengue and hospitalization
– Sanofi Pasteur intends to file for registration in several endemic countries in 2015 –
– Dengue vaccine candidate would address an urgent unmet medical need in tropical and sub-tropical regions of the world
3 November 2014
[Excerpt]
…Sanofi Pasteur’s phase III efficacy clinical study program for its dengue vaccine candidate was conducted in over 31,000 participants across 10 endemic countries in Asia2 and Latin America. Sanofi Pasteur will file for registration of its vaccine candidate and, subject to regulatory approval, the world’s first dengue vaccine could be available in the second half of 2015.
“We plan to submit the vaccine for licensure in 2015 in endemic countries where dengue is a public health priority,” said Olivier Charmeil, President and CEO of Sanofi Pasteur. “We are committed to supporting countries’ ambitions to significantly impact the human and economic
burden of dengue through comprehensive vaccination programs. Our goal is to help meet the WHO’s objectives to reduce dengue mortality by 50% and morbidity by 25% by 2020.”…
… Sanofi Pasteur is already producing the vaccine in a newly dedicated production facility in Neuville-sur-Saône, France, which will be capable of providing timely supply of large quantities of vaccines to meet the global public health demand…

:: Sanofi Pasteur Announces FDA Approval of Updated Prescribing Information for Fluzone High-Dose Vaccine for Adults 65 and Older
Includes New Data Showing Fluzone High-Dose Vaccine More Efficacious Than Standard-Dose Fluzone Vaccine –
SWIFTWATER, Pa., Nov. 3, 2014 /PRNewswire/ — Sanofi Pasteur, the vaccines division of Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental biologics license application (sBLA) for Fluzone® High-Dose (Influenza Vaccine) to include efficacy data in the Prescribing Information. These data demonstrate that Fluzone High-Dose vaccine provided improved protection against influenza (“the flu”) compared to standard-dose Fluzone vaccine (trivalent intramuscular formulation) in adults 65 years of age and older.
The Prescribing Information for Fluzone High-Dose vaccine now includes data from a large-scale, multi-center efficacy and safety trial published in the August 14, 2014, issue of The New England Journal of Medicine (DOI: 10.1056/NEJMoa1315727).[i]…

IOM/NRC Meeting: Research Priorities to Inform Public Health and Medical Practice for Domestic Ebola Virus Disease (EVD): A Workshop
November 3, 2014
An ad hoc committee, under the auspices of the Institute of Medicine in collaboration with the National Research Council will organize a one-day workshop that will explore potential research priorities arising as a result of the emergence of Ebola Virus Disease (EVD), a hemorrhagic disease caused by a filovirus, in the United States. The workshop will focus primarily on basic science and environmental health research issues of specific concern to affected and potentially affected U.S. communities. The workshop will help inform future research that could be conducted under real-world conditions (i.e., during an event) that would provide public health officials and the general public with additional accurate information about virus transmission, mitigation of health risks, and appropriate measures to prevent the spread of disease. Specific topics that may be discussed include:
:: Routes of transmission and persistence of the virus to inform public health practice.
– Examine characteristics and properties of the virus that influence the stability and viability of EVD in order to continue to inform public health efforts, handling of potentially infectious materials, and protection of at-risk responders.
– Assess methods of viral inactivation and alternative solutions for effective disinfection of contaminated surfaces.
– Explore considerations regarding the real-world use of personal protective equipment (PPE) among non-traditional workers or others that may be exposed to infected individuals or contaminated materials, including real-time training and education.
:: Strategies to address issues of concern to healthcare workers and the general public, including the use of PPE and personal protective behaviors to prevent spread and reduce exposure.

The committee will develop the agenda for the workshop session, select and invite speakers and discussants, and moderate the discussions. An individually authored brief workshop summary based on the presentations and discussions held during the workshop will be prepared by a designated rapporteur in accordance with institutional guidelines.

The American Journal of Bioethics
Volume 14, Issue 12, 2014
http://www.tandfonline.com/toc/uajb20/current
[Target Article: this article is accompanies by seven articles providing analysis and comment]
Shared Vulnerabilities in Research
Eric Chwanga*
DOI:10.1080/15265161.2014.964872
pages 3-11
Published online: 04 Nov 2014
Abstract
The U.S. Code of Federal Regulations governing federally funded research on human subjects assumes that harmful research is sometimes morally justifiable because the beneficiaries of that research share a particular vulnerability with its subjects. In this article, I argue against this assumption, which occurs in every subpart of the Code of Federal Regulations that deals with specific vulnerable populations (pregnant women, fetuses, neonates, prisoners, and children). I argue that shared vulnerability is no exception to the general principle that harming one person in order to benefit another is no more justifiable if the two people have traits in common. Further, shared vulnerability is not a reasonable proxy for any morally relevant desideratum of research, in particular the desire to benefit the worst off, the desire to avoid exploitation, and the desire to use vulnerable populations in research only when necessary.

American Journal of Preventive Medicine
Volume 47, Issue 5, p531-688 November 2014
http://www.ajpmonline.org/current

Assessing Immunization Interventions in the Women, Infants, and Children (WIC) Program
Tracy N. Thomas, MPH, MSc, Maureen S. Kolasa, MPH, Fan Zhang, PhD, Abigail M. Shefer, MD
National Center for Immunization and Respiratory Disease, CDC, Atlanta, Georgia
Published Online: September 13, 2014
DOI: http://dx.doi.org/10.1016/j.amepre.2014.06.017
Abstract
Background
Vaccination promotion strategies are recommended in Women, Infants, and Children (WIC) settings for eligible children at risk for under-immunization due to their low-income status.
Purpose
To determine coverage levels of WIC and non-WIC participants and assess effectiveness of immunization intervention strategies.
Methods
The 2007–2011 National Immunization Surveys were used to analyze vaccination histories and WIC participation among children aged 24–35 months. Grantee data on immunization activities in WIC settings were collected from the 2010 WIC Linkage Annual Report Survey. Coverage by WIC eligibility and participation status and grantee-specific coverage by intervention strategy were determined at 24 months for select antigens. Data were collected 2007–2011 and analyzed in 2013.
Results
Of 13,183 age-eligible children, 5,699 (61%, weighted) had participated in WIC, of which 3,404 (62%, weighted) were current participants. In 2011, differences in four or more doses of the diphtheria, tetanus toxoid, and acellular pertussis (DTaP) vaccine by WIC participation status were observed: 86% (ineligible); 84% (current); 77% (previous); and 69% (never-eligible). Children in WIC exposed to an immunization intervention strategy had higher coverage levels than WIC-eligible children who never participated, with differences as great as 15% (DTaP).
Conclusions
Children who never participated in WIC, but were eligible, had the lowest vaccination coverage. Current WIC participants had vaccination coverage comparable to more affluent children, and higher coverage than previous WIC participants.

Annals of Internal Medicine
4 November 2014, Vol. 161. No. 9
http://annals.org/issue.aspx

Ideas and Opinions | 4 November 2014
Toward Tuberculosis Elimination in Low-Incidence Countries: Reflections From a Global Consultation
Knut Lönnroth, MD, PhD, MSc; Giovanni Battista Migliori, MD; and Mario Raviglione, MD
Article and Author Information
Ann Intern Med. 2014;161(9):670-671. doi:10.7326/M14-1888
In July 2014, participants from 36 countries and experts in the field met to discuss a global framework for eliminating tuberculosis in low-incidence countries. This commentary discusses the framework for elimination, which will require high-level political commitment, strong public health programs, social justice, international solidarity, and investment in research…

American Journal of Tropical Medicine and Hygiene
November 2014; 91 (5)
http://www.ajtmh.org/content/current

Global Health Research in Narrative: A Qualitative Look at the FICRS-F Experience
Benjamin Bearnot, Alexandra Coria, Brian Scott Barnett, Eva H. Clark, Matthew G. Gartland, Devan Jaganath, Emily Mendenhall, Lillian Seu, Ayaba G. Worjoloh, Catherine Lem Carothers, Sten H. Vermund and Douglas C. Heimburger*
Author Affiliations
New York University School of Medicine, New York, New York; Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; Vanderbilt University School of Medicine, Nashville, Tennessee; Vanderbilt Institute for Global Health, Nashville, Tennessee; University of Alabama at Birmingham, Birmingham, Alabama; University of California at Los Angeles, Los Angeles, California; Georgetown University, Washington, District of Columbia; Duke University Medical Center, Durham, North Carolina
Abstract.
For American professional and graduate health sciences trainees, a mentored fellowship in a low- or middle-income country (LMIC) can be a transformative experience of personal growth and scientific discovery. We invited 86 American trainees in the Fogarty International Clinical Research Scholars and Fellows Program and Fulbright–Fogarty Fellowship 2011–2012 cohorts to contribute personal essays about formative experiences from their fellowships. Nine trainees contributed essays that were analyzed using an inductive approach. The most frequently addressed themes were the strong continuity of research and infrastructure at Fogarty fellowship sites, the time-limited nature of this international fellowship experience, and the ways in which this fellowship period was important for shaping future career planning. Trainees also addressed interaction with host communities vis-à-vis engagement in project implementation. These qualitative essays have contributed insights on how a 1-year mentored LMIC-based research training experience can influence professional development, complementing conventional evaluations. Full text of the essays is available at http://fogartyscholars.org/.

Short-Term Global Health Education Programs Abroad: Disease Patterns Observed in Haitian Migrant Worker Communities Around La Romana, Dominican Republic
Brian J. Ferrara, Elizabeth Townsley, Christopher R. MacKay, Henry C. Lin and Lawrence C. Loh*
Author Affiliations
Departments of Internal Medicine and Pediatrics, Baystate Medical Center, Springfield, Massachusetts; University of Massachusetts Medical School, Worcester, Massachusetts; Department of Gastroenterology, Hepatology, and Nutrition, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania; The 53rd Week, Brooklyn, New York; Divisions of Global Health and Clinical Public Health, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada; Department of Family Medicine, University of British Columbia, Vancouver, British Columbia, Canada
Abstract.
The possibility of encountering rare tropical disease presentations is commonly described as a benefit derived by developed world medical trainees participating in clinical service-oriented short-term global health experiences in the developing world. This study describes the health status of a population served by a short-term experience conducted by a North American institute, and the results of a retrospective review are used to identify commonly encountered diseases and discuss their potential educational value. Descriptive analysis was conducted on 1,024 encounter records collected over four unique 1-week-long trips by a North American institution serving Haitian migrant workers in La Romana, Dominican Republic. The top five diagnoses seen in the clinic were gastroesophageal reflux disease (GERD), hypertension (HTN), upper respiratory infections, otitis media, and fungal skin infection. On occasion, diagnoses unique to an indigent tropical population were encountered (e.g., dehydration, malnutrition, parasites, and infections.). These findings suggest a similarity between frequently encountered diagnoses on a short-term clinical service trip in Dominican Republic and primary care presentations in developed world settings, which challenges the assumption that short-term service experiences provide exposure to rare tropical disease presentations. These findings also represent additional data that can be used to better understand the health and healthcare planning among this vulnerable population of Haitian migrant workers

Epidemiology of Sexually Transmitted Infections in Rural Southwestern Haiti: The Grand’Anse Women’s Health Study
Kathleen A. Jobe, Robert F. Downey*, Donna Hammar, Lori Van Slyke and Terri A. Schmidt
Author Affiliations
University of Washington, Division of Emergency Medicine, Seattle, Washington; Seattle–King County Disaster Team, Seattle, Washington; Sysmex America, Inc., Laboratory Application Services, San Diego, California; Providence Health and Services, North Coast Urgent Care Clinics, Seaside, Oregon; MultiCare Health System, Department of Social Work, Tacoma, Washington; Oregon Health & Science University, Department of Emergency Medicine, Portland, Oregon
Abstract.
The study attempts to define socioeconomic, clinical, and laboratory correlates in vaginitis and other sexually transmitted infections in rural southwestern Haiti. A convenience sample of subjects recruited from a rural women’s health clinic and attending an established clinic at the Haitian Health Foundation (HHF) clinic was studied. A standardized history and physical examination, including speculum examination, and collection of blood, urine, and vaginal swabs were obtained from the women at the rural clinic. Additional vaginal swab samples only for Nucleic Acid Amplification Test (NAAT) testing were obtained from women at the HHF clinic in Jérémie. Laboratory results from Leon subjects were positive for Gardnerella vaginalis in 41% (41 of 100), Trichomonas vaginalis in 13.5% (14 of 104), Candida sp. in 9% (9 of 100), Mycoplasma genitalium in 6.7% (7 of 104), Chlamydia trachomatis in 1.9% (2 of 104), and Neisseria gonorrhea in 1% (1 of 104) of patients. Human immunodeficiency virus (HIV) antibody tests were negative in 100% (103 of 103) of patients, and syphilis antibody testing was positive for treponemal antibodies in 7.7% (8 of 104) patients. For subjects from the HHF, 19.9% were positive for T. vaginalis, 11.9% were positive for C. trachomatis, 10.1% were positive for M. genitalium, and 4.1% were positive for N. gonorrhea. Infections with G. vaginalis, T. vaginalis, and Candida were the most common. N. gonorrhea, C. trachomatis, Candida sp., T. vaginalis, and M. genitalium infections were associated with younger age (less than 31 years old).

Cholera at the Crossroads: The Association Between Endemic Cholera and National Access to Improved Water Sources and Sanitation
Benjamin L. Nygren*, Anna J. Blackstock and Eric D. Mintz
Author Affiliations
Division of Foodborne, Waterborne and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
Abstract.
We evaluated World Health Organization (WHO) national water and sanitation coverage levels and the infant mortality rate as predictors of endemic cholera in the 5-year period following water and sanitation coverage estimates using logistic regression, receiver operator characteristic curves, and different definitions of endemicity. Each was a significant predictors of endemic cholera at P < 0.001. Using a value of 250 for annual cases reported in 3 of 5 years, a national water access level of 71% has 65% sensitivity and 65% specificity in predicting endemic cholera, a sanitation access level of 39% has 63% sensitivity and 62% specificity, and an infant mortality rate of 65/1,000 has 67% sensitivity and 69% specificity. Our findings reveal the tradeoff between sensitivity and specificity for these predictors of endemic cholera and highlight the substantial uncertainty in the data. More accurate global surveillance data will enable more precise characterization of the benefits of improved water and sanitation.

BMC Health Services Research
(Accessed 8 November 2014)
http://www.biomedcentral.com/bmchealthservres/content

Research article
Frontline health workers as brokers: provider perceptions, experiences and mitigating strategies to improve access to essential medicines in South Africa
Bvudzai Priscilla Magadzire1*, Ashwin Budden2, Kim Ward13, Roger Jeffery4 and David Sanders1
Author Affiliations
BMC Health Services Research 2014, 14:520 doi:10.1186/s12913-014-0520-6
Published: 5 November 2014
Abstract (provisional)
Background
Front-line health providers have a unique role as brokers (patient advocates) between the health system and patients in ensuring access to medicines (ATM). ATM is a fundamental component of health systems. This paper examines in a South African context supply- and demand- ATM barriers from the provider perspective using a five dimensional framework: availability (fit between existing resources and clients? needs); accessibility (fit between physical location of healthcare and location of clients); accommodation (fit between the organisation of services and clients? practical circumstances); acceptability (fit between clients? and providers? mutual expectations and appropriateness of care) and affordability (fit between cost of care and ability to pay).
Methods
This cross-sectional, qualitative study uses semi-structured interviews with nurses, pharmacy personnel and doctors. Thirty-six providers were purposively recruited from six public sector Community Health Centres in two districts in the Eastern Cape Province representing both rural and urban settings. Content analysis combined structured coding and grounded theory approaches. Finally, the five dimensional framework was applied to illustrate the interconnected facets of the issue.
Results
Factors perceived to affect ATM were identified. Availability of medicines was hampered by logistical bottlenecks in the medicines supply chain; poor public transport networks affected accessibility. Organization of disease programmes meshed poorly with the needs of patients with comorbidities and circular migrants who move between provinces searching for economic opportunities, proximity to services such as social grants and shopping centres influenced where patients obtain medicines. Acceptability was affected by, for example, HIV related stigma leading patients to seek distant services. Travel costs exacerbated by the interplay of several ATM barriers influenced affordability. Providers play a brokerage role by adopting flexible prescribing and dispensing for `stable? patients and aligning clinic and social grant appointments to minimise clients? routine costs. Occasionally they reported assisting patients with transport money.
Conclusion
All five ATM barriers are important and they interact in complex ways. Context-sensitive responses which minimise treatment interruption are needed. While broad-based changes encompassing all disease programmes to improve ATM are needed, a beginning could be to assess the appropriateness, feasibility and sustainability of existing brokerage mechanisms.

Research article
Cost-effectiveness analysis in Developing Nations: A cross sectional survey about Exposure, Interest and Barriers
Jackson Musuuza, Mendel E Singer, Anna Mandalakas and Achilles Katamba
Author Affiliations
BMC Health Services Research 2014, 14:539 doi:10.1186/s12913-014-0539-8
Published: 4 November 2014
Abstract (provisional)
Background
Cost effectiveness analysis (CEA) is a useful tool for allocation of constrained resources, yet CEA methodologies are rarely taught or implemented in developing nations. We aimed to assess exposure to, and interest in CEA, and identify barriers to implementation in Uganda.
Methods
A cross-sectional survey was carried out in Uganda using a newly developed self-administered questionnaire (via online and paper based approaches), targeting the main health care actors as identified by a previous study.
Results
Overall, there was a 68% response rate, with a 92% (69/75) response rate among the paper-based respondents compared to a 40% (26/65) rate with the online respondents. Seventy eight percent (74/95) of the respondents had no exposure to CEA. None of those with a master of medicine degree had any CEA exposure, and 80% of technical officers, who are directly involved in policy formulation, had no CEA exposure. Barriers to CEA identified by more than 50% of the participants were: lack of information technology (IT) infrastructure (hardware and software); lack of local experts in the field of CEA; lack of or limited local data; limited CEA training in schools; equity or ethical issues; and lack of training grants incorporating CEA. 93% reported a lot of interest in learning to conduct CEA, and over 95% felt CEA was important for clinical decision making and policy formulation.
Conclusions
Among health care actors in Uganda, there is very limited exposure to, but substantial interest in conducting CEA and including it in clinical decision making and health care policy formation. Capacity to undertake CEA needs to be built through incorporation into medical training and use of regional approaches.

BMC Research Notes
(Accessed 8 November 2014)
http://www.biomedcentral.com/bmcresnotes/content

Hepatitis B vaccination status and Needle-stick and Sharps-related Injuries among medical school students in Nepal: a cross-sectional study
Suraj Bhattarai, Smriti KC, Pranil MS Pradhan, Sami Lama and Suman Rijal
Author Affiliations
BMC Research Notes 2014, 7:774 doi:10.1186/1756-0500-7-774
Published: 3 November 2014
Abstract (provisional)
Background
Hepatitis B is a dreadful infectious disease and a major global health problem. Health-care workers including clinical students are more vulnerable to such infections and non-sterile occupational exposures as their daily activities are closely related to patient’s blood and body fluids.
Methods
A descriptive cross sectional study was conducted at B.P. Koirala Institute of Health Sciences (BPKIHS), Dharan, Nepal from July till October 2012. All medical, dental and nursing students were surveyed for their Hepatitis B vaccination status and only those students in clinical rotations were surveyed for the prevalence and pattern of Needle-stick and Sharps-related Injuries (NSSIs) using a pre-tested, semi-structured, self-administered questionnaire. Descriptive and inferential statistics was used to analyze the data.
Results
Majority (86.5%) of students were vaccinated against Hepatitis B of which 83.7% had completed full doses. Among non-vaccinated students, 43.2% reported the main reason for non-vaccination as lack of vaccination programs. Out of 210 respondents from clinical rotations, 90 students (42.8%) reported at least one injury. Among those injured, two students reported exposure to Human immunodeficiency virus (HIV) positive cases and four to Hepatitis B virus (HBV) positive cases. Most of the injuries (44%) occurred during Internal Medicine posting and the most common sharp involved (56.3%) was Hypodermic needle. Most injuries (35.6%) occurred while manipulating needle into patients. Following exposure, only 11.4% took Post exposure prophylaxis and 19.54% went for a Post-exposure serology test.
Conclusions
Needle-stick and Sharps-related Injuries occur frequently among health care workers including trainee students keeping them at high risk for acquiring dreadful infections like HBV, HCV and HIV. They need to be protected from unwarranted hazards by adopting routine Hepatitis B vaccination programs and by reinforcing education regarding universal precautions.

Clinical Infectious Diseases (CID)
Volume 59 Issue 10 November 15, 2014
http://cid.oxfordjournals.org/content/current
Impact of Repeated Vaccination on Vaccine Effectiveness Against Influenza A(H3N2) and B During 8 Seasons
Huong Q. McLean, Mark G. Thompson, Maria E. Sundaram, Jennifer K. Meece, David L. McClure, Thomas C. Friedrich, and Edward A. Belongia
Clin Infect Dis. (2014) 59 (10): 1375-1385 doi:10.1093/cid/ciu680
Abstract
OPEN ACCESS
The effect of prior influenza vaccination history on vaccine effectiveness was assessed in a community cohort over 8 seasons. Current- and previous-season vaccination generated similar levels of protection; vaccine-induced protection was greatest for individuals with no recent vaccination history.

Complexity
November/December 2014 Volume 20, Issue 2 Pages fmi–fmi, 1–81
http://onlinelibrary.wiley.com/doi/10.1002/cplx.v20.2/issuetoc

The Simply complex
Exponential growth in Ebola outbreak since May 14, 2014
Allen G. Hunt*
Article first published online: 18 OCT 2014
DOI: 10.1002/cplx.21615
Excerpt
Contrary to general opinion, the current Ebola outbreak in West Africa followed an exponential growth curve starting already in mid-May. The death toll followed an exponential growth curve with almost the same time constant, allowing direct calculation of the mortality of the outbreak. This value remained steady at about 72%, contrary to the estimate of the World Health Organization of slightly above 50%. Until the last 2 weeks, the projected date at which the number of infected individuals would reach 100,000 had remained steady at January 19. Updated statistics from September 6 advanced that date by at least a month. Estimates suggest that over 20,000 already have been infected, exceeding the number that the WHO has declared could be the eventual outcome…

Epidemiology and Infection
Volume 142 – Issue 12 – December 2014
http://journals.cambridge.org/action/displayIssue?jid=HYG&tab=currentissue

Review Articles
Pneumococcal and meningococcal infection
A review of the evidence to inform pneumococcal vaccine recommendations for risk groups aged 2 years and older
A. STEENSa1a2 c1, D. F. VESTRHEIMa1, I. S. AABERGEa1, B. S. WIKLUNDa1, J. STORSAETERa1, M. A. RIISE BERGSAKERa1, K. RØNNINGa1 and E. FURUSETHa1
a1 Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway
a2 European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
SUMMARY
For decades, vaccination with the 23-valent polysaccharide pneumococcal vaccine (PPV23) has been available for risk groups aged ≥2 years to prevent invasive pneumococcal disease (IPD). Recently, a 13-valent pneumococcal conjugated vaccine (PCV13) has been licensed for use in all age groups. PCV13 may induce better protection than PPV23 because of different immunogenic properties. This called for a revision of vaccine recommendations for risk groups. We therefore reviewed literature on risk groups for IPD, and effectiveness and safety of pneumococcal vaccines and supplemented that with information from public health institutes, expert consultations and data on IPD epidemiology. We included 187 articles. We discuss the implications of the heterogenic vulnerability for IPD within and between risk groups, large indirect effects of childhood immunization, and limited knowledge on additional clinical benefits of PCV13 in combination with PPV23 for the Norwegian recommendations. These are now step-wise and consider the need for vaccination, choice of pneumococcal vaccines, and re-vaccination interval by risk group.

Original Papers
Pneumococcal and meningococcal infection
The effect of distance on observed mortality, childhood pneumonia and vaccine efficacy in rural Gambia
S. M. A. ZAMANa1 c1, J. COXa2, G. C. ENWEREa1, C. BOTTOMLEYa3, B. M. GREENWOODa2 and F. T. CUTTSa1
a1 Medical Research Council Unit, Banjul, The Gambia
a2 Department of Disease Control, London School of Hygiene & Tropical Medicine, London, UK
a3 Medical Research Council Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
SUMMARY
We investigated whether straight-line distance from residential compounds to healthcare facilities influenced mortality, the incidence of pneumonia and vaccine efficacy against pneumonia in rural Gambia. Clinical surveillance for pneumonia was conducted on 6938 children living in the catchment areas of the two largest healthcare facilities. Deaths were monitored by three-monthly home visits. Children living >5 km from the two largest healthcare facilities had a 2•78 [95% confidence interval (CI) 1•74–4•43] times higher risk of all-cause mortality compared to children living within 2 km of these facilities. The observed rate of clinical and radiological pneumonia was lower in children living >5 km from these facilities compared to those living within 2 km [rate ratios 0•65 (95% CI 0•57–0•73) and 0•74 (95% CI 0•55–0•98), respectively]. There was no association between distance and estimated pneumococcal vaccine efficacy. Geographical access to healthcare services is an important determinant of survival and pneumonia in children in rural Gambia.

Short Reports
Hepatitis
Hepatitis B vaccination for healthcare personnel in American Samoa: pre-implementation survey for policy decision
K. N. LYa1 c1, H. ROBERTSa1, R. E. WILLIAMSa1, Y. MASUNU-FALEAFAGAa2, J. DROBENIUCa1, S. KAMILIa1 and E. H. TESHALEa1
a1 Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, USA
a2 American Samoa Immunization Program, American Samoa Department of Health, Pago Pago, American Samoa
SUMMARY
American Samoa does not have a hepatitis B vaccination policy for healthcare personnel (HCP). Consequently, hepatitis B has remained a health threat to HCP. In this study, we performed a cross-sectional study and examined demographic and risk information and hepatitis B vaccination, testing, and serostatus in hospital employees in American Samoa. Of 604 hospital employees, 231 (38•2%) participated, and of these, 158 (68•4%) were HCP. Of HCP participants, 1•9% had chronic hepatitis B infection, 36•1% were susceptible, and 60•8% were immune. Nearly half of HCP participants reported history of needlestick injury. Overall, participants’ knowledge of their hepatitis B infection and vaccination status was low. These data support the adoption of a hepatitis B vaccination policy for HCP by American Samoa, as currently recommended by the World Health Organization and the US Centers for Disease Control and Prevention. Adherence to the policy could be monitored as a way to measure protection.